US20170369426A1 - Antibacterial agents - Google Patents

Antibacterial agents Download PDF

Info

Publication number
US20170369426A1
US20170369426A1 US15/615,276 US201715615276A US2017369426A1 US 20170369426 A1 US20170369426 A1 US 20170369426A1 US 201715615276 A US201715615276 A US 201715615276A US 2017369426 A1 US2017369426 A1 US 2017369426A1
Authority
US
United States
Prior art keywords
hydroxy
compound
phenyl
methyl
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/615,276
Inventor
Brian D. Patterson
Qing Lu
James Bradley Aggen
Paola Dozzo
Ramesh Annasaheb Kasar
Martin Sheringham linsell
Timothy Robert Kane
Micah James Gliedt
Darin James Hildebrandt
Glenn A. McEnroe
Frederick Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achaogen Inc
Original Assignee
Achaogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achaogen Inc filed Critical Achaogen Inc
Priority to US15/615,276 priority Critical patent/US20170369426A1/en
Assigned to ACHAOGEN, INC. reassignment ACHAOGEN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AGGEN, JAMES BRADLEY, KASAR, Ramesh Annasaheb, PATTERSON, BRIAN D., COHEN, FREDERICK, DOZZO, PAOLA, HILDEBRANDT, DARIN JAMES, KANE, TIMOTHY ROBERT, LINSELL, MARTIN SHERINGHAM, LU, QING, GLIEDT, MICAH JAMES, MCENROE, GLENN A.
Publication of US20170369426A1 publication Critical patent/US20170369426A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/04—Sulfinic acids; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/08—Sulfenic acids; Derivatives thereof
    • C07C313/10—Sulfenic acids; Esters thereof
    • C07C313/12—Sulfenic acids; Esters thereof having sulfur atoms of sulfenic groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/42—Y being a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

  • This invention pertains generally to treating infections caused by gram-negative bacteria. More specifically, the invention described herein pertains to treating gram-negative infections by inhibiting activity of UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC).
  • the present invention provides small molecule inhibitors of LpxC, pharmaceutical formulations containing such inhibitors, methods of treating subjects with such pharmaceutical formulations, and methods of preparing such pharmaceutical formulations and inhibitors.
  • the invention described herein pertains to treating gram-negative infections by administering compounds capable of inhibiting activity of UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC), either alone or in combination with administering a second antibacterial compound.
  • UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC) either alone or in combination with administering a second antibacterial compound.
  • LpxC the enzyme uridyldiphospho-3-O—(R-hydroxydecanoyl)-N-acetylglucosamine deacetylase
  • LpxC is essential for survival and presents an ideal target for antibiotic activity in Gram-negative bacterial species.
  • an object of this invention to provide compounds and combinations of such compounds for use in the preparation of non-toxic antibacterials and other pharmaceuticals capable of inhibiting gram-negative bacterial infections.
  • the present invention provides novel compounds, pharmaceutical formulations including the compounds, methods of inhibiting UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC), and methods of treating gram-negative bacterial infections.
  • UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC) methods of treating gram-negative bacterial infections.
  • A is selected from the group consisting of:
  • G is selected from the group consisting of:
  • D is selected from the group consisting of:
  • W is N or N + —O ⁇ ;
  • the invention provides compounds of formula II:
  • A is selected from the group consisting of:
  • G is selected from the group consisting of:
  • D is selected from the group consisting of:
  • the present invention provides a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
  • the present invention provides a pharmaceutical composition comprising a compound of Formula II, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
  • the present invention provides a pharmaceutical composition comprising an effective amount of an antibacterial compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
  • the present invention provides a pharmaceutical composition comprising an effective amount of an antibacterial compound of Formula II, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
  • the present invention provides a method of inhibiting a deacetylase enzyme in gram-negative bacteria, thereby affecting bacterial growth, comprising administering to a subject in need of such inhibition an LpxC-inhibitory compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof.
  • the present invention provides a method of inhibiting a deacetylase enzyme in gram-negative bacteria, thereby affecting bacterial growth, comprising administering to a subject in need of such inhibition an LpxC-inhibitory compound of Formula II or a stereoisomer or pharmaceutically acceptable salt thereof.
  • the present invention provides a method of inhibiting LpxC, thereby modulating the virulence of a bacterial infection, comprising administering to a subject in need of such inhibition an LpxC-inhibitory compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof.
  • the present invention provides a method of inhibiting LpxC, thereby modulating the virulence of a bacterial infection, comprising administering to a subject in need of such inhibition an LpxC-inhibitory compound of Formula II or a stereoisomer or pharmaceutically acceptable salt thereof.
  • the present invention provides a method for treating a subject having a bacterial infection comprising administering to the subject in need thereof an antibacterially effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof.
  • the present invention provides a method for treating a subject having a bacterial infection comprising administering to the subject in need thereof an antibacterially effective amount of a compound of Formula II, or a stereoisomer or pharmaceutically acceptable salt thereof.
  • the bacterial infection is a gram-negative bacterial infection.
  • the subject is a mammal and in certain embodiments, a human.
  • the present invention provides a method of administering an antibacterially effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, to a subject infected with a fermentative or non-fermentative gram-negative bacteria.
  • the present invention provides a method of administering an antibacterially effective amount of a compound of Formula II, or a stereoisomer or pharmaceutically acceptable salt thereof, to a subject infected with a fermentative or non-fermentative gram-negative bacteria.
  • bacteria examples include Pseudomonas aeruginosa, Stenotrophomonas maltophila, Burkholderia cepacia, Alcaligenes xylosoxidans, Enterobacteriaceae, Haemophilus, Franciscellaceae (e.g., Franciscella tularensis ) and Neisseria species.
  • the present invention provides a method of administering an antibacterially effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, to a subject infected with gram-negative bacteria.
  • the present invention provides a method of administering an antibacterially effective amount of a compound of Formula II, or a stereoisomer or pharmaceutically acceptable salt thereof, to a subject infected with gram-negative bacteria.
  • Enterobacteriaceae such as Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Providencia, Yersinia (e.g., Yersinia pestis ), Morganella, Cedecea, Edwardsiella species and Escherichia coli.
  • the present invention provides novel compounds, methods for inhibiting LpxC in gram-negative bacteria, and novel methods for treating bacterial infections.
  • the compounds provided herein can be formulated into pharmaceutical formulations and medicaments that are useful in the methods of the invention.
  • the invention also provides for the use of the compounds in preparing medicaments and pharmaceutical formulations, for use of the compounds in inhibiting LpxC, and for use of the compounds in treating bacterial infections in a subject.
  • the invention further provides compositions and methods for treating gram-negative infections by administering compounds capable of inhibiting activity of UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC), either alone or in combination with administering a second antibacterial compound
  • LpxC is an abbreviation that stands for UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase.
  • Alkyl refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms. This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH 3 —), ethyl (CH 3 CH 2 —), n-propyl (CH 3 CH 2 CH 2 —), isopropyl ((CH 3 ) 2 CH—), n-butyl (CH 3 CH 2 CH 2 CH 2 —), isobutyl ((CH 3 ) 2 CHCH 2 —), sec-butyl ((CH 3 )(CH 3 CH 2 )CH—), t-butyl ((CH 3 ) 3 C—), n-pentyl (CH 3 CH 2 CH 2 CH 2 CH 2 —), and neopentyl ((CH 3 ) 3 CCH 2 —).
  • Alkoxy refers to the group —O-alkyl, wherein alkyl is as defined herein. Alkoxy includes methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, n-pentoxy, and the like.
  • Amino refers to the group —NH 2 .
  • Primary alcohol refers to the group -alkyl-OH, wherein the hydroxyl radical is connected to a primary carbon. Examples include —CH 2 OH (hydroxymethyl), —CH 2 CH 2 OH (hydroxymethyl) and —CH(CH 3 )CH 2 OH (1-hydroxypropan-2-yl).
  • Alkenyl refers to straight chain or branched hydrocarbyl groups having from 2 to 6 carbon atoms and preferably 2 to 4 carbon atoms and having at least 1 and preferably from 1 to 2 sites of vinyl (>C ⁇ C ⁇ ) unsaturation. Such groups are exemplified by vinyl, allyl, and but-3-en-1-yl. Included within this term are the cis and trans isomers or mixtures of these isomers.
  • Alkynyl refers to straight or branched monovalent hydrocarbyl groups having from 2 to 6 carbon atoms and preferably 2 to 3 carbon atoms and having at least 1 and preferably from 1 to 2 sites of acetylenic —C ⁇ C— unsaturation. Examples of such alkynyl groups include acetylenyl (—C ⁇ CH), and propargyl (—CH 2 C ⁇ CH).
  • Carboxyl or “carboxy” refers to —COOH or salts thereof.
  • Cycloalkyl refers to cyclic alkyl groups of from 3 to 13 carbon atoms having single. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like.
  • Halo or “halogen” refers to fluoro, chloro, bromo, and iodo and is typically fluoro or chloro.
  • “Hydroxy” or “hydroxyl” refers to the group —OH.
  • Heterocycle refers to a saturated or unsaturated group having a single ring, and having from 3 to 15 ring atoms, including 1 to 4 hetero atoms. These ring atoms are selected from the group consisting of nitrogen, sulfur, or oxygen. In one implementation, the nitrogen and/or sulfur atom(s) of the heterocyclic group are optionally oxidized to provide for the N-oxide, —S(O)—, or —SO 2 — moieties.
  • Niro refers to the group —NO 2 .
  • Niroso refers to the group —NO.
  • Oxo refers to the atom ( ⁇ O).
  • “Substituted” refers to a group having one or more hydrogens replaced with substituents selected from the group consisting of alkoxy, acyl, acylamino, acyloxy, amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, amidino, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, cyano, guanidino, halo, hydroxy, nitro, SO 3 H, sulfonyl, sulfonyloxy, thioacyl, thiol, and alkylthio, wherein said substituents are as defined herein.
  • substituted also refers to a group having two hydrogens replaced with a single double bonded oxygen atom (an oxo group) or a single double bonded sulfur atom (thioxo).
  • the substituted group has 1 to 3 of the aforementioned substituents. In other implementations, the substituted group has 1 to 2 of the aforementioned substituents
  • “Sulfonyl” refers to the group —SO 2 -alkyl, —SO 2 -substituted alkyl, —SO 2 — alkenyl, —SO 2 -substituted alkenyl, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl are as defined herein. Sulfonyl includes groups such as methyl-SO 2 —.
  • “Sulfonyloxy” refers to the group —OSO 2 -alkyl, —OSO 2 -substituted alkyl, —OSO 2 -alkenyl, —OSO 2 -substituted alkenyl, —OSO 2 -alkynyl, —OSO 2 -substituted alkynyl, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl are as defined herein.
  • Thioacyl refers to the groups H—C(S)—, alkyl-C(S)—, substituted alkyl-C(S)—, alkenyl-C(S)—, substituted alkenyl-C(S)—, alkynyl-C(S)—, and substituted alkynyl-C(S)—, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl are as defined herein.
  • Thiol refers to the group —SH.
  • Thioxo refers to the atom ( ⁇ S).
  • Alkylthio refers to the group —S-alkyl, wherein alkyl is as defined herein.
  • sulfur may be oxidized to —S(O)—.
  • the sulfoxide may exist as one or more stereoisomers.
  • substituents that are not explicitly defined herein are arrived at by naming the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment.
  • substituent “arylalkyloxycarbonyl” refers to the group (aryl)-(alkyl)-O—C(O)—.
  • references to a certain element such as hydrogen or H is meant to include all isotopes of that element.
  • a substituent group is defined to include hydrogen or H, it also includes deuterium and tritium.
  • the subject invention also includes isotopically-labeled compounds of the present invention, that are structurally identical to those disclosed herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F and 36 Cl, respectively.
  • Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds and of said prodrugs that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
  • Certain isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
  • isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out known or referenced procedures and by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • Stereoisomers refer to compounds that have same atomic connectivity but different atomic arrangement in space. Stereoisomers include cis-trans isomers, E and Z isomers, enantiomers, and diastereomers.
  • Tautomer refers to alternate forms of a molecule that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a —N ⁇ C(H)—NH— ring atom arrangement, such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.
  • a person of ordinary skill in the art would recognize that other tautomeric ring atom arrangements are possible.
  • Subject refers to human and non-human animals, especially mammals.
  • “Pharmaceutically acceptable salt” refers to pharmaceutically acceptable salts of a compound, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, phosphate, sulfate and the like.
  • “Pharmaceutically effective amount” and “therapeutically effective amount” refer to an amount of a compound sufficient to treat a specified disorder or disease or one or more of its symptoms and/or to prevent the occurrence of the disease or disorder.
  • Co-administration can be in the form of a single formulation (combining, for example, a compound of the present invention and a second antibacterial agent with pharmaceutically acceptable excipients, optionally segregating the two active ingredients in different excipient mixtures designed to independently control their respective release rates and durations) or by independent administration of separate formulations containing the active agents. “Co-administration” further includes concurrent administration (administration of a compound of the present invention and a second antibacterial agent at the same time) and time varied administration (administration of a compound of the present invention at a time different from that of the second antibacterial agent), as long as both the compound of the present invention and the second antibacterial agent are present in the body in therapeutically effective concentrations during at least partially overlapping times.
  • antibacterial agent refers to agents that have either bactericidal or bacteriostatic activity.
  • inhibiting the growth indicates that the rate of increase in the numbers of a population of a particular bacterium is reduced. Thus, the term includes situations in which the bacterial population increases but at a reduced rate, as well as situations where the growth of the population is stopped, as well as situations where the numbers of the bacteria in the population are reduced or the population even eliminated. If an enzyme activity assay is used to screen for inhibitors, one can make modifications in uptake/efflux, solubility, half-life, etc. to compounds in order to correlate enzyme inhibition with growth inhibition.
  • the activity of antibacterial agents is not necessarily limited to bacteria but may also encompass activity against parasites, virus, and fungi.
  • the invention provides compounds of formula I:
  • A is selected from the group consisting of:
  • G is selected from the group consisting of:
  • D is selected from the group consisting of:
  • W is N or N + —O ⁇ ;
  • the invention provides compounds of formula II:
  • A is selected from the group consisting of:
  • G is selected from the group consisting of:
  • D is selected from the group consisting of:
  • A is substituted C 3 -C 6 cycloalkyl, wherein at least one substituent is selected from hydroxy and hydroxyalkyl. In certain embodiments, A is substituted C 3 -C 6 cycloalkyl, wherein at least one substituent is hydroxymethyl. For example, in certain embodiments A is hydroxymethylcyclopropyl. In other embodiments, A is substituted C 3 -C 6 cycloalkyl, wherein at least one substituent is hydroxy.
  • G is —C ⁇ C—C ⁇ C—.
  • D is
  • R 1 is hydrogen.
  • R 2 is hydrogen.
  • E is —C(CH 3 ) 2 SCH 3 .
  • E is —C(CH 3 ) 2 S(O) 2 CH 3 .
  • E is —C(CH 3 ) 2 S(O)CH 3 .
  • E is —C(O)NHCH 3 .
  • the compounds of the invention include the compounds of Table I below.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
  • the invention provides a method of inhibiting a deacetylase enzyme in a gram-negative bacteria, thereby affecting bacterial growth, comprising administering to a subject in need of such inhibition a compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof.
  • the invention provides a method of inhibiting LpxC, thereby modulating the virulence of a bacterial infection, comprising administering to a subject in need of such inhibition a compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof.
  • the IC 50 value of the compound is less than or equal to 10 ⁇ M with respect to LpxC.
  • the IC 50 value is less than or equal to 1 ⁇ M, is less than or equal to 0.1 ⁇ M, is less than or equal to 0.050 ⁇ M, is less than or equal to 0.030 ⁇ M, is less than or equal to 0.025 ⁇ M, or is less than or equal to 0.010 ⁇ M.
  • the invention provides a method for treating a subject having a gram-negative bacterial infection comprising administering to the subject in need thereof an antibacterially effective amount of a compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof.
  • the invention provides a method of administering a therapeutically effective amount of a compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof to a subject infected with a fermentative or non-fermentative gram-negative bacteria.
  • fermentative or non-fermentative gram-negative bacteria include Pseudomonas aeruginosa, Stenotrophomonas maltophila, Burkholderia cepacia, Alcaligenes xylosoxidans, Enterobacteriaceae, Haemophilus, Franciscellaceae (e.g., Franciscella tularensis ) and Neisseria species.
  • the invention provides a method of administering an inhibitory amount of a compound described herein to gram-negative bacteria, such as Enterobacteriaceae which is selected from the group consisting of organisms such as Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Providencia, Yersinia (e.g., Yersinia pestis ), Morganella, Cedecea, Edwardsiella species and Escherichia coli.
  • Enterobacteriaceae which is selected from the group consisting of organisms such as Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Providencia, Yersinia (e.g., Yersinia pestis ), Morganella, Cedecea, Edwardsiella species and Escherichia coli.
  • the subject may be a mammal, and in some embodiments, a human.
  • Bacterial infections susceptible to treatment according to the present invention include primary infections and co-infections caused by a species of bacteria and one or more additional infectious agents such as, for example, bacteria, virus, parasite and fungus.
  • Compounds of the invention can be used for treating conditions caused by the bacterial production of endotoxin and, in particular, by gram-negative bacteria and bacteria that use LpxC in the biosynthesis of lipopolysaccharide (LPS) or endotoxin.
  • LPS lipopolysaccharide
  • Compounds of the invention also are useful in treating conditions that are caused or exacerbated by the bacterial production of lipid A and LPS or endotoxin, such as sepsis, septic shock, systemic inflammation, localized inflammation, chronic obstructive pulmonary disease (COPD) and acute exacerbations of chronic bronchitis (AECB).
  • treatment includes the administration of a compound of the invention, or a combination of compounds of the invention, optionally with a second agent wherein the second agent is a second antibacterial agent or a non-antibacterial agent.
  • non-antibacterial agents include antiendotoxins including endotoxin receptor-binding antibodies, endotoxin-binding antibodies, anti-CD14-binding protein antibodies, antilipopolysaccharide-binding protein antibodies and tyrosine kinase inhibitors.
  • compounds of the present invention may also be used with non-antibacterial agents administered via inhalation.
  • Representative non-antibacterial agents used in this treatment include anti-inflammatory steroids, non-steroidal anti-inflammatory agents, bronchiodilators, mucolytics, anti-asthma therapeutics and lung fluid surfactants.
  • the non-antibacterial agent may be albuterol, salbuterol, budesonide, beclomethasone, dexamethasone, nedocromil, beclomethasone, fluticasone, flunisolide, triamcinolone, ibuprofin, rofecoxib, naproxen, celecoxib, nedocromil, ipratropium, metaproterenol, pirbuterol, salmeterol, formoterol, indacaterol, bronchiodilators, mucolytics, calfactant, beractant, poractant alfa, surfaxin or pulmozyme (also called domase alfa).
  • Compounds of the invention can be used alone or in combination with a second antibacterial agent for the treatment of a serious or chronic respiratory tract infection including serious lung and nosocomial infections such as those caused by Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Serratia marcescens, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Burkholderia cepacia, Alcaligenes xylosoxidans, Flavobacterium meningosepticum, Providencia stuartii and Citrobacter freundi , community lung infections such as those caused by Haemophilus Influenzae, Legionella species, Moraxella catarrhalis, Branhamella catarrhalis, Enterobacter species, Klebsiella species , and Proteus species, infections caused by other bacterial species such as
  • compounds of the present invention When used for treating subjects infected with gram-negative bacterial infections, compounds of the present invention can be used to sensitize gram-negative bacteria to the effects of a second agent.
  • the present invention provides novel combinations of compounds including a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, as well as methods for treating subjects infected with gram-negative bacteria.
  • novel combinations provided herein can be formulated into pharmaceutical formulations and medicaments that are useful in the methods of the invention.
  • the invention also provides for the use of the novel combinations in preparing medicaments and pharmaceutical formulations, for use of the combinations in treating bacterial infections in a subject.
  • a second antibacterial agent is used in combination with a compound of Formula I, or stereoisomer or pharmaceutically acceptable salt thereof.
  • suitable second antibactieral agents include, but are not limited to, vancomycin, linezolid, azithromycin, imipenem, teicoplanin, daptomycin, clindamycin, rifampin, cefotaxime, gentamicin, novobiocin or telavancin.
  • the antibacterial agent is vancomycin, teicoplanin, rifampin, azithromycin, telavancin or novobiocin.
  • the second antibacterial agent is vancomycin or rifampin.
  • the second antibacterial agent and/or the compound of Formula I, or stereoisomer or pharmaceutically acceptable salt thereof is administered at a sub-therapeutic dose, wherein a subtherapeutic dose is a dose that would be insufficient to treat bacterial infections, if administered alone.
  • compositions of the present invention comprise a therapeutically effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, formulated together with one or more pharmaceutically acceptable carriers or diluents.
  • pharmaceutically acceptable carrier means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • materials that can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulf
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally (as by intravenous, intramuscular or subcutaneous injection), intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, or as an oral or nasal spray, or a liquid aerosol or dry powder formulation for inhalation.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as wetting agents, e
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, 1% lidocaine, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • delayed absorption of a parenterally administered drug form may be accomplished by dissolving or suspending the drug in an oil vehicle.
  • injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations may also be prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories that can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, acetyl alcohol and
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the antibacterial compounds can also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulations, ear drops, and the like are also contemplated as being within the scope of this invention.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • compositions of the invention may also be formulated for delivery as a liquid aerosol or inhalable dry powder.
  • Liquid aerosol formulations may be nebulized predominantly into particle sizes that can be delivered to the terminal and respiratory bronchioles where bacteria reside in subjects with bronchial infections, such as chronic bronchitis and pneumonia.
  • Pathogenic bacteria are commonly present throughout airways down to bronchi, bronchioli and lung parenchema, particularly in terminal and respiratory bronchioles. During exacerbation of infection, bacteria can also be present in alveoli.
  • Liquid aerosol and inhalable dry powder formulations are preferably delivered throughout the endobronchial tree to the terminal bronchioles and eventually to the parenchymal tissue.
  • Aerosolized formulations of the invention may be delivered using an aerosol forming device, such as a jet, vibrating porous plate or ultrasonic nebulizer, preferably selected to allow the formation of a aerosol particles having with a mass medium average diameter predominantly between 1 to 5 ⁇ m.
  • the formulation preferably has balanced osmolarity ionic strength and chloride concentration, and the smallest aerosolizable volume able to deliver effective dose of the compounds of the invention to the site of the infection.
  • the aerosolized formulation preferably does not impair negatively the functionality of the airways and does not cause undesirable side effects.
  • Aerosolization devices suitable for administration of aerosol formulations of the invention include, for example, jet, vibrating porous plate, ultrasonic nebulizers and energized dry powder inhalers, that are able to nebulize the formulation of the invention into aerosol particle size predominantly in the size range from 1-5 ⁇ m. Predominantly in this application means that at least 70% but preferably more than 90% of all generated aerosol particles are 1 to 5 ⁇ m range.
  • a jet nebulizer works by air pressure to break a liquid solution into aerosol droplets. Vibrating porous plate nebulizers work by using a sonic vacuum produced by a rapidly vibrating porous plate to extrude a solvent droplet through a porous plate.
  • An ultrasonic nebulizer works by a piezoelectric crystal that shears a liquid into small aerosol droplets.
  • suitable devices including, for example, AeroNeb and AeroDose vibrating porous plate nebulizers (AeroGen, Inc., Sunnyvale, Calif.), Sidestream7 nebulizers (Medic-Aid Ltd., West Wales, England), Pari LC7 and Pari LC Star7 jet nebulizers (Pari Respiratory Equipment, Inc., Richmond, Va.), and Aerosonic (DeVilbiss Medizinische Kunststoffische Kunststoffische Kunststoffische Kunststoffische Kunststoffische Kunststoffische Kunststoffische Kunststoffische Kunststoffische Kunststoffetechnik (Deutschland) GmbH, Heiden, Germany) and UltraAire7 (Omron Healthcare, Inc., Vernon Hills, Ill.) ultrasonic nebulizers.
  • Compounds of the invention may also be formulated for use as topical powders and sprays that can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound to the body.
  • dosage forms can be made by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin.
  • the rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • bacterial infections are treated or prevented in a subject such as a human or lower mammal by administering to the subject a therapeutically effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, in such amounts and for such time as is necessary to achieve the desired result.
  • a “therapeutically effective amount” of a compound of the invention is meant a sufficient amount of the compound to treat bacterial infections, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
  • the total daily dose of the compounds of this invention administered to a human or other mammal in single or in divided doses can be in amounts, for example, from 0.01 to 200 mg/kg body weight or more usually from 0.1 to 50 mg/kg body weight. In certain embodiments, the total daily dose administered to a human or other mammal is from 1.0 to 100 mg/kg body weight or from 5.0 to 25 mg/kg body weight. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.
  • treatment regimens according to the present invention comprise administration to a subject in need of such treatment from about 10 mg to about 15 g of the compound(s) of this invention per day in single or multiple doses, more usually, from 100 mg to 5 g, and even more usually from 250 mg to 1 g per day in single or multiple doses.
  • compositions for use in the present invention can be in the form of sterile, non-pyrogenic liquid solutions or suspensions, coated capsules, suppositories, lyophilized powders, transdermal patches or other forms known in the art.
  • a “kit” as used in the instant application includes a container for containing the pharmaceutical compositions and may also include divided containers such as a divided bottle or a divided foil packet.
  • the container can be in any conventional shape or form as known in the art that is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a resealable bag (for example, to hold a “refill” of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule.
  • the container employed can depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle that is in turn contained within a box.
  • Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil that is opposite from the direction in which the recesses were formed.
  • the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet.
  • the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
  • the written memory aid is of the type containing information and/or instructions for the physician, pharmacist or other health care provider, or subject, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen that the tablets or capsules so specified should be ingested or a card that contains the same type of information.
  • a memory aid is a calendar printed on the card e.g., as follows “First Week, Monday, Tuesday,” . . . etc. . . “Second Week, Monday, Tuesday, . . . ” etc.
  • Other variations of memory aids will be readily apparent.
  • a “daily dose” can be a single tablet or capsule or several tablets or capsules to be taken on a given day.
  • a daily dose of one or more compositions of the kit can consist of one tablet or capsule while a daily dose of another one or more compositions of the kit can consist of several tablets or capsules.
  • kits are a dispenser designed to dispense the daily doses one at a time in the order of their intended use.
  • the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen.
  • a memory-aid is a mechanical counter, that indicates the number of daily doses that has been dispensed.
  • a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal that, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
  • kits of the present invention may also include, in addition to a compound of the present invention, one or more additional pharmaceutically active compounds.
  • the additional compound second antibacterial.
  • the additional compounds may be administered in the same dosage form as the compound of the present invention or in a different dosage form. Likewise, the additional compounds can be administered at the same time as the compound of the present invention or at different times.
  • compositions of the present compounds may also be used in combination with other known antibacterial agents of similar spectrum to (1) enhance treatment of severe gram-negative infections covered by the spectrum of this compound or (2) add coverage in severe infections in which multiple organisms are suspected in which another agent of a different spectrum may be required in addition to this compound.
  • Potential agents include members of the aminoglycosides, penicillins, cephalosporins, fluoroquinolones, macrolides, glycopeptides, lipopeptides and oxazolidinones.
  • the treatment can involve administering a composition having both a compound of the present invention and a second antibacterial compound or administration of a compound of the present inventive compounds followed by or preceded by administration of a second antibacterial agent.
  • HPLC Angilent 1200; Mobile Phase: A: water (0.01% TFA) B:ACN (0.01% TFA); Column: ZORBAX SB-C18, 5 um, 4.6*150 mm; Oven Temperature: 50° C.
  • LCMS Angilent 1200; Mobile Phase: A: water(0.01% TFA) B:ACN(0.01% TFA), Column: SunFire C18 3.5 um, 4.6*50 mm; Oven Temperature: 50° C.
  • GCMS Agilent instrument (7890A Series gas chromatograph with a Mass Selective Detector 5975C; injector volume: 1 mL; initial column temperature: 40° C.; final column temperature: 250 C; ramp time: 8.4 min; gas flow rate: 1.2 mL/min; column: 5% phenyl methyl silox, Model:Agilent 19091s-433:325C, dimensions: 30.0 m′250 u m′0.25 um)
  • NMR Bruker AVANCE III 400 MHz, UltraShield-PlusTM Digital NMR
  • the analytical columns were Phenomenex Luna C18(2) reversed phase, 10 ⁇ m, 100 ⁇ , axia packed, 2.0 ⁇ 50 mm and the preparative columns were Phenomenex Luna C18(2) reversed phase, 10 ⁇ m, 100 ⁇ , axia packed, 21.2 ⁇ 250 or 50 ⁇ 250 mm.
  • a gradient elution was used, typically starting with 100% water and progressing to 100% acetonitrile over a varying lengths of time All solvents contained 0.1% acetic acid (AcOH).
  • Compounds were detected by ultraviolet light (UV) absorption at either 220 or 254 nm.
  • TLC thin layer chromatography
  • Mass spectrometric analysis was performed on one of three LCMS instruments: a Waters System. (Alliance HT HPLC and a Micromass ZQ mass spectrometer; Column: Eclipse XDB-C—18, 2.1 ⁇ 50 mm; solvent system: 5-95% (or 35-95%, or 65-95% or 95-95%) acetonitrile in water with 0.05% TFA; flow rate 0.8 mL/min; molecular weight range 500-1500; cone Voltage 20 V; column temperature 40° C.) or a Hewlett Packard System (Series 1100 HPLC; Column: Eclipse XDB-C18, 2.1 ⁇ 50 mm; solvent system: 1-95% acetonitrile in water with 0.05% TFA; flow rate 0.4 mL/min; molecular weight range 150-850; cone Voltage 50 V; column temperature 30° C.).
  • a Waters System. Alliance HT HPLC and a Micromass ZQ mass spectrometer
  • GCMS analysis was performed on a Hewlet Packard instrument (HP6890 Series gas chromatograph with a Mass Selective Detector 5973; injector volume: 1 ⁇ L; initial column temperature: 50° C.; final column temperature: 250 C; ramp time: 20 min; gas flow rate: 1 mL/min; column: 5% phenyl methyl siloxane, Model #HP 190915-443, dimensions: 30.0 m ⁇ 25 m ⁇ 0.25 m); or Agilent instrument (7890A Series gas chromatograph with a Mass Selective Detector 5975C; injector volume: 1 mL; initial column temperature: 40° C.; final column temperature: 250 C; ramp time: 8.4 min; gas flow rate: 1.2 mL/min; column: 5% phenyl methyl silox, Model:Agilent 19091s-433:325C, dimensions: 30.0 m′250 u m′0.25 um).
  • Nuclear magnetic resonance (NMR) analysis was performed with a Varian 300 MHz NMR (Palo Alto, Calif.). and a Varian Unity Enova 400 MHz NMR spectrometer (Palo Alto, Calif.), or Bruker AVANCE III 400 MHz, UltraShield-PlusTM Digital NMR.
  • the spectral reference was either TMS or the known chemical shift of the solvent.
  • Ethynyltrimethylsilane (82.4 g, 0.84 mol) was added dropwise over 10 min under a nitrogen atmosphere to a solution of methyl 4-bromobenzoate (150 g, 0.7 mol), PdCl 2 (PPh 3 ) 2 (15 g, 0.021 mol) and CuI (13 g, 0.07 mol) in TEA (1.5 L) and the reaction was stirred at 90° C. for 30 minutes. Solids were collected by filtration and washed with EtOAc (5 ⁇ 500 mL).
  • the two layers were partitioned and the aqueous layer was back-extracted with methyl-THF (230 mL).
  • the organic layers were washed with 2M HCl (2 ⁇ 230 mL), water (230 ml), and brine (230 ml), dried over Na 2 SO 4 and filtered.
  • the organic layer was concentrated under reduced pressure until the solution turned cloudy, then heptane (230 mL) was added.
  • the resulting solution was concentrated under reduced pressure to 5 volumes and then additional heptane (230 mL) was added.
  • the resulting solution was concentrated to 5 volumes to give a slurry.
  • reaction mixture was partitioned between 2N aqueous sodium hydroxide and ethyl acetate.
  • the aqueous layer was acidified with conc HCl and extracted with ethyl acetate.
  • the resulting organic layer was washed with water, saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give 6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)benzo[b]thiophene-2-carboxylic acid (7.2, 900 mg, 3.3 mmol, 85%).
  • Bacterial isolates were cultivated from ⁇ 70° C. frozen stocks by overnight passages at 35° C. in ambient air on Mueller-Hinton agar (Beckton Dickinson, Franklin Lakes, N.J.). Clinical isolates tested were obtained from various geographically diverse hospitals in the US and abroad (Focus Diagnostics, Herndon, Va. and JMI, North Liberty, Iowa). Quality control strains were from the American Type Culture Collection (ATCC; Rockville, Md.).
  • MICs Minimum Inhibitory Concentrations
  • CFU colony-forming units
  • Drug dilutions and inocula were made in sterile, cation adjusted Mueller-Hinton Broth (Beckton Dickinson). An inoculum volume of 100 ⁇ L was added to wells containing 100 ⁇ L of broth with 2-fold serial dilutions of drug. All inoculated microdilution trays were incubated in ambient air at 35° C. for 18-24 hr.
  • A MIC's of 1.0 ⁇ g/mL or less
  • B MIC's of greater than 1.0 ⁇ g/mL to 8.0 ⁇ g/mL
  • C MIC's of greater than 8.0 ⁇ g/mL to 16.0 ⁇ g/mL
  • AECO is Escherichia coli ATCC25922.
  • AKPN is Klebsiella pneumonia ATCC43816.
  • APAE is Pseudomonas aeruginosa ATCC27853.
  • organic compounds according to the invention may exhibit the phenomenon of tautomerism.
  • chemical structures within this specification can only represent one of the possible tautomeric forms, it should be understood that the invention encompasses any tautomeric form of the drawn structure.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Antibacterial compounds of formula (I) are provided:
Figure US20170369426A1-20171228-C00001
as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.

Description

    I. CROSS-REFERENCE TO RELATED APPLICATION
  • This application is a continuation of U.S. application Ser. No. 15/179,751, filed Jun. 10, 2016 (now allowed), which is a continuation of U.S. application Ser. No. 14/537,048, filed Nov. 10, 2014, now U.S. Pat. No. 9,403,758, which is a continuation of International PCT Application No. PCT/US2013/040571, which was filed on May 10, 2013, which claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 61/645,439, filed May 10, 2012. The foregoing applications are incorporated herein by reference in their entireties.
    • II. BACKGROUND OF THE INVENTION
  • A. Field of the Invention
  • This invention pertains generally to treating infections caused by gram-negative bacteria. More specifically, the invention described herein pertains to treating gram-negative infections by inhibiting activity of UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC). The present invention provides small molecule inhibitors of LpxC, pharmaceutical formulations containing such inhibitors, methods of treating subjects with such pharmaceutical formulations, and methods of preparing such pharmaceutical formulations and inhibitors. The invention described herein pertains to treating gram-negative infections by administering compounds capable of inhibiting activity of UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC), either alone or in combination with administering a second antibacterial compound.
  • B. Introduction
  • Over the past several decades, the frequency of antimicrobial resistance and its association with serious infectious diseases have increased at alarming rates. The problem of antibacterial resistance is compounded by the existence of bacterial strains resistant to multiple antibacterials. Thus there is a need for new antibacterials, particularly antibacterials with novel mechanisms of action. A previously unexploited but highly conserved target, LpxC, provides a new opportunity for developing broad-spectrum antibacterial small molecules that comprise a new class of active bactericidal chemical entities that should encounter little, if any, naturally-occurring, target-related resistance. LpxC (the enzyme uridyldiphospho-3-O—(R-hydroxydecanoyl)-N-acetylglucosamine deacetylase) is present across all Gram-negative bacterial species of interest and is involved in the first committed step in outer membrane biosynthesis. Thus LpxC is essential for survival and presents an ideal target for antibiotic activity in Gram-negative bacterial species.
  • Researchers have identified some compounds with antibacterial activity that target lipid A biosynthesis. For example, Jackman et al. (J. Biol. Chem., 2000, 275(15), 11002-11009); Wyckoff et al. (Trends in Microbiology, 1998, 6(4), 154-159); U.S. Patent Application Publication No. 2001/0053555 (published 20 Dec. 2001, corresponding to International PCT Publication No. WO 98/18754, published 7 May 1998); International PCT Publication No. WO 00/61134 (published 19 Oct. 2000); U.S. Patent Application Publication No. 2004/0229955 (published 18 Nov. 2004); International PCT Publication No. WO 2008/027466 (published 6 Mar. 2008); International PCT Publication No. WO 2008/105515 (published 4 Sep. 2008); International PCT Publication No. WO 2008/154642 (published 18 Dec. 2008); International PCT Publication No. WO 2009/158369 (published 30 Dec. 2009); International PCT Publication No. WO 2010/017060 (published 11 Feb. 2010); International PCT Publication No. WO 2010/024356 (published 4 Mar. 2010); International PCT Publication No. WO 2010/031750 (published 25 Mar. 2010); International PCT Publication No. WO 2010/032147 (published 25 Mar. 2010); International PCT Publication No. WO 2010/100475 (published 10 Sep. 2010); International PCT Publication No. WO 2011/045703 (published 21 Apr. 2011); International PCT Publication No. WO 2011/073845 (published 23 Jun. 2011); and International PCT Publication No. WO 2011/132712 (published 27 Oct. 2011) all disclose compounds having antibacterial anti-LpxC activity. The commercial development of these LpxC inhibitors has been complicated by toxicity of these compounds in mammalian animals at concentrations at or near those required for antibacterial activity.
  • Although there have been advances in the field, there remains a need for LpxC inhibitors that have activity as bactericidal agents against gram-negative bacteria and have an acceptable efficacy and toxicity/tolerance profile. It is, accordingly, an object of this invention to provide compounds and combinations of such compounds for use in the preparation of non-toxic antibacterials and other pharmaceuticals capable of inhibiting gram-negative bacterial infections.
    • III. BRIEF SUMMARY OF THE INVENTION
  • The present invention provides novel compounds, pharmaceutical formulations including the compounds, methods of inhibiting UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC), and methods of treating gram-negative bacterial infections.
  • In one aspect the invention provides compounds of formula I:
  • Figure US20170369426A1-20171228-C00002
  • and stereoisomers and, pharmaceutically acceptable salts thereof, wherein
  • A is selected from the group consisting of:
      • (a) substituted C1-C6 alkyl, wherein at least one substituent is hydroxy; and
      • (b) substituted C3-C6 cycloalkyl, wherein at least one substituent is selected from hydroxy and hydroxyalkyl;
  • G is selected from the group consisting of:
      • (a) —C≡C—;
      • (b) —CH═CH—C≡C—;
      • (c) —C≡C—CH═CH—;
      • (d) —C≡C—C≡C—;
  • Figure US20170369426A1-20171228-C00003
  • and
      • (g) phenyl; and
  • D is selected from the group consisting of:
  • Figure US20170369426A1-20171228-C00004
  • wherein W is N or N+—O−;
  • Figure US20170369426A1-20171228-C00005
  • wherein
      • R1 and R2 are each independently selected from hydrogen and methyl; and
      • E is —C(CH3)2SCH3, —C(CH3)2S(O)CH3, —C(CH3)2S(O)2CH3, or —C(O)NHCH3.
  • In one aspect, the invention provides compounds of formula II:
  • Figure US20170369426A1-20171228-C00006
  • and stereoisomers and pharmaceutically acceptable salts thereof, wherein
  • A is selected from the group consisting of:
      • (a) substituted C1-C6 alkyl, wherein at least one substituent is hydroxy; and
      • (b) substituted C3-C6 cycloalkyl, wherein at least one substituent is selected from hydroxy and hydroxyalkyl;
  • G is selected from the group consisting of:
      • (a) —C≡C—;
      • (b) —CH═CH—C≡C—;
      • (c) —C≡C—CH═CH—;
      • (d) —C≡C—C≡C—;
  • Figure US20170369426A1-20171228-C00007
  • and
      • (g) phenyl; and
  • D is selected from the group consisting of:
  • Figure US20170369426A1-20171228-C00008
      • wherein
        • Q is O or NR, wherein R is hydrogen or an unsubstituted C1-C3 alkyl;
        • R1 and R2 independently are selected from the group consisting of hydrogen, and substituted or unsubstituted C1-C3 alkyl, or R1 and R2, together with the carbon atom to which they are attached, form an unsubstituted C3-C6 cycloalkyl group or an unsubstituted 4-6 membered heterocyclic group; and
        • R3 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C6-alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl.
  • In another aspect, the present invention provides a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. In another aspect, the present invention provides a pharmaceutical composition comprising a compound of Formula II, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
  • In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of an antibacterial compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of an antibacterial compound of Formula II, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
  • In another aspect, the present invention provides a method of inhibiting a deacetylase enzyme in gram-negative bacteria, thereby affecting bacterial growth, comprising administering to a subject in need of such inhibition an LpxC-inhibitory compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof. In another aspect, the present invention provides a method of inhibiting a deacetylase enzyme in gram-negative bacteria, thereby affecting bacterial growth, comprising administering to a subject in need of such inhibition an LpxC-inhibitory compound of Formula II or a stereoisomer or pharmaceutically acceptable salt thereof.
  • In another aspect, the present invention provides a method of inhibiting LpxC, thereby modulating the virulence of a bacterial infection, comprising administering to a subject in need of such inhibition an LpxC-inhibitory compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof. In another aspect, the present invention provides a method of inhibiting LpxC, thereby modulating the virulence of a bacterial infection, comprising administering to a subject in need of such inhibition an LpxC-inhibitory compound of Formula II or a stereoisomer or pharmaceutically acceptable salt thereof.
  • In another aspect, the present invention provides a method for treating a subject having a bacterial infection comprising administering to the subject in need thereof an antibacterially effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof. In another aspect, the present invention provides a method for treating a subject having a bacterial infection comprising administering to the subject in need thereof an antibacterially effective amount of a compound of Formula II, or a stereoisomer or pharmaceutically acceptable salt thereof. In a more specific embodiment of the method of treatment, the bacterial infection is a gram-negative bacterial infection. In a further specific embodiment the subject is a mammal and in certain embodiments, a human.
  • In another aspect, the present invention provides a method of administering an antibacterially effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, to a subject infected with a fermentative or non-fermentative gram-negative bacteria. In another aspect, the present invention provides a method of administering an antibacterially effective amount of a compound of Formula II, or a stereoisomer or pharmaceutically acceptable salt thereof, to a subject infected with a fermentative or non-fermentative gram-negative bacteria. Examples of such bacteria include Pseudomonas aeruginosa, Stenotrophomonas maltophila, Burkholderia cepacia, Alcaligenes xylosoxidans, Enterobacteriaceae, Haemophilus, Franciscellaceae (e.g., Franciscella tularensis) and Neisseria species.
  • In another aspect, the present invention provides a method of administering an antibacterially effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, to a subject infected with gram-negative bacteria. In another aspect, the present invention provides a method of administering an antibacterially effective amount of a compound of Formula II, or a stereoisomer or pharmaceutically acceptable salt thereof, to a subject infected with gram-negative bacteria. Examples of such bacteria include Enterobacteriaceae, such as Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Providencia, Yersinia (e.g., Yersinia pestis), Morganella, Cedecea, Edwardsiella species and Escherichia coli.
  • These and other aspects of the invention will be evident upon reference to the following detailed description.
    • IV. DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides novel compounds, methods for inhibiting LpxC in gram-negative bacteria, and novel methods for treating bacterial infections. The compounds provided herein can be formulated into pharmaceutical formulations and medicaments that are useful in the methods of the invention. The invention also provides for the use of the compounds in preparing medicaments and pharmaceutical formulations, for use of the compounds in inhibiting LpxC, and for use of the compounds in treating bacterial infections in a subject. The invention further provides compositions and methods for treating gram-negative infections by administering compounds capable of inhibiting activity of UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC), either alone or in combination with administering a second antibacterial compound
    • A. Definitions
  • The following abbreviations and definitions are used throughout this application:
  • “LpxC” is an abbreviation that stands for UDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase.
  • As used herein, the following definitions shall apply unless otherwise indicated.
  • “Alkyl” refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms. This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH3—), ethyl (CH3CH2—), n-propyl (CH3CH2CH2—), isopropyl ((CH3)2CH—), n-butyl (CH3CH2CH2CH2—), isobutyl ((CH3)2CHCH2—), sec-butyl ((CH3)(CH3CH2)CH—), t-butyl ((CH3)3C—), n-pentyl (CH3CH2CH2CH2CH2—), and neopentyl ((CH3)3CCH2—).
  • “Alkoxy” refers to the group —O-alkyl, wherein alkyl is as defined herein. Alkoxy includes methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, n-pentoxy, and the like.
  • “Amino” refers to the group —NH2.
  • “Primary alcohol” refers to the group -alkyl-OH, wherein the hydroxyl radical is connected to a primary carbon. Examples include —CH2OH (hydroxymethyl), —CH2CH2OH (hydroxymethyl) and —CH(CH3)CH2OH (1-hydroxypropan-2-yl).
  • “Alkenyl” refers to straight chain or branched hydrocarbyl groups having from 2 to 6 carbon atoms and preferably 2 to 4 carbon atoms and having at least 1 and preferably from 1 to 2 sites of vinyl (>C═C<) unsaturation. Such groups are exemplified by vinyl, allyl, and but-3-en-1-yl. Included within this term are the cis and trans isomers or mixtures of these isomers.
  • “Alkynyl” refers to straight or branched monovalent hydrocarbyl groups having from 2 to 6 carbon atoms and preferably 2 to 3 carbon atoms and having at least 1 and preferably from 1 to 2 sites of acetylenic —C≡C— unsaturation. Examples of such alkynyl groups include acetylenyl (—C≡CH), and propargyl (—CH2C≡CH).
  • “Carboxyl” or “carboxy” refers to —COOH or salts thereof.
  • “Cyano” or “nitrile” refers to the group —CN.
  • “Cycloalkyl” refers to cyclic alkyl groups of from 3 to 13 carbon atoms having single. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like.
  • “Guanidino” refers to the group —NHC(═NH)NH2.
  • “Halo” or “halogen” refers to fluoro, chloro, bromo, and iodo and is typically fluoro or chloro.
  • “Hydroxy” or “hydroxyl” refers to the group —OH.
  • “Heterocycle,” “heterocyclic,” and “heterocyclyl” refer to a saturated or unsaturated group having a single ring, and having from 3 to 15 ring atoms, including 1 to 4 hetero atoms. These ring atoms are selected from the group consisting of nitrogen, sulfur, or oxygen. In one implementation, the nitrogen and/or sulfur atom(s) of the heterocyclic group are optionally oxidized to provide for the N-oxide, —S(O)—, or —SO2— moieties.
  • “Nitro” refers to the group —NO2.
  • “Nitroso” refers to the group —NO.
  • “Oxo” refers to the atom (═O).
  • “Substituted” refers to a group having one or more hydrogens replaced with substituents selected from the group consisting of alkoxy, acyl, acylamino, acyloxy, amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, amidino, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, cyano, guanidino, halo, hydroxy, nitro, SO3H, sulfonyl, sulfonyloxy, thioacyl, thiol, and alkylthio, wherein said substituents are as defined herein. In certain substituted cyclic groups, “substituted” also refers to a group having two hydrogens replaced with a single double bonded oxygen atom (an oxo group) or a single double bonded sulfur atom (thioxo). In some implementations, the substituted group has 1 to 3 of the aforementioned substituents. In other implementations, the substituted group has 1 to 2 of the aforementioned substituents
  • “Sulfonyl” refers to the group —SO2-alkyl, —SO2-substituted alkyl, —SO2— alkenyl, —SO2-substituted alkenyl, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl are as defined herein. Sulfonyl includes groups such as methyl-SO2—.
  • “Sulfonyloxy” refers to the group —OSO2-alkyl, —OSO2-substituted alkyl, —OSO2-alkenyl, —OSO2-substituted alkenyl, —OSO2-alkynyl, —OSO2-substituted alkynyl, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl are as defined herein.
  • “Thioacyl” refers to the groups H—C(S)—, alkyl-C(S)—, substituted alkyl-C(S)—, alkenyl-C(S)—, substituted alkenyl-C(S)—, alkynyl-C(S)—, and substituted alkynyl-C(S)—, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl are as defined herein.
  • “Thiol” refers to the group —SH.
  • “Thioxo” refers to the atom (═S).
  • “Alkylthio” refers to the group —S-alkyl, wherein alkyl is as defined herein. In other implementations, sulfur may be oxidized to —S(O)—. The sulfoxide may exist as one or more stereoisomers.
  • Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment. For example, the substituent “arylalkyloxycarbonyl” refers to the group (aryl)-(alkyl)-O—C(O)—.
  • Generally, reference to a certain element such as hydrogen or H is meant to include all isotopes of that element. For example, if a substituent group is defined to include hydrogen or H, it also includes deuterium and tritium.
  • The subject invention also includes isotopically-labeled compounds of the present invention, that are structurally identical to those disclosed herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F and 36Cl, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds and of said prodrugs that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out known or referenced procedures and by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • “Stereoisomer” and “stereoisomers” refer to compounds that have same atomic connectivity but different atomic arrangement in space. Stereoisomers include cis-trans isomers, E and Z isomers, enantiomers, and diastereomers.
  • “Tautomer” refers to alternate forms of a molecule that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a —N═C(H)—NH— ring atom arrangement, such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles. A person of ordinary skill in the art would recognize that other tautomeric ring atom arrangements are possible.
  • “Subject” refers to human and non-human animals, especially mammals.
  • “Pharmaceutically acceptable salt” refers to pharmaceutically acceptable salts of a compound, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, phosphate, sulfate and the like.
  • “Pharmaceutically effective amount” and “therapeutically effective amount” refer to an amount of a compound sufficient to treat a specified disorder or disease or one or more of its symptoms and/or to prevent the occurrence of the disease or disorder.
  • “Co-administration” can be in the form of a single formulation (combining, for example, a compound of the present invention and a second antibacterial agent with pharmaceutically acceptable excipients, optionally segregating the two active ingredients in different excipient mixtures designed to independently control their respective release rates and durations) or by independent administration of separate formulations containing the active agents. “Co-administration” further includes concurrent administration (administration of a compound of the present invention and a second antibacterial agent at the same time) and time varied administration (administration of a compound of the present invention at a time different from that of the second antibacterial agent), as long as both the compound of the present invention and the second antibacterial agent are present in the body in therapeutically effective concentrations during at least partially overlapping times.
  • The term “antibacterial agent” refers to agents that have either bactericidal or bacteriostatic activity. The term “inhibiting the growth” indicates that the rate of increase in the numbers of a population of a particular bacterium is reduced. Thus, the term includes situations in which the bacterial population increases but at a reduced rate, as well as situations where the growth of the population is stopped, as well as situations where the numbers of the bacteria in the population are reduced or the population even eliminated. If an enzyme activity assay is used to screen for inhibitors, one can make modifications in uptake/efflux, solubility, half-life, etc. to compounds in order to correlate enzyme inhibition with growth inhibition. The activity of antibacterial agents is not necessarily limited to bacteria but may also encompass activity against parasites, virus, and fungi.
  • Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is as “including, but not limited to”.
  • Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
    • B. Compounds, Compositions and Use Thereof
  • In one aspect, the invention provides compounds of formula I:
  • Figure US20170369426A1-20171228-C00009
  • and stereoisomers, pharmaceutically acceptable salts, and esters thereof, wherein
  • A is selected from the group consisting of:
      • (a) substituted C1-C6 alkyl, wherein at least one substituent is hydroxy; and
      • (b) substituted C3-C6 cycloalkyl, wherein at least one substituent is selected from hydroxy and hydroxyalkyl;
  • G is selected from the group consisting of:
      • (a) —C≡C—;
      • (b) —CH═CH—C≡C—;
      • (c) —C≡C—CH═CH—;
      • (d) —C≡C—C≡C—;
  • Figure US20170369426A1-20171228-C00010
  • and
      • (g) phenyl; and
  • D is selected from the group consisting of:
  • Figure US20170369426A1-20171228-C00011
  • wherein W is N or N+—O−;
  • Figure US20170369426A1-20171228-C00012
  • wherein
      • R1 and R2 are each independently selected from hydrogen and methyl; and
      • E is —C(CH3)2SCH3, —C(CH3)2S(O)CH3, —C(CH3)2S(O)2CH3, or —C(O)NHCH3.
  • In one aspect, the invention provides compounds of formula II:
  • Figure US20170369426A1-20171228-C00013
  • and stereoisomers, pharmaceutically acceptable salts, and esters thereof, wherein
  • A is selected from the group consisting of:
      • (a) substituted C1-C6 alkyl, wherein at least one substituent is hydroxy; and
      • (b) substituted C3-C6 cycloalkyl, wherein at least one substituent is selected from hydroxy and hydroxyalkyl;
  • G is selected from the group consisting of:
      • (a) —C≡C—;
      • (b) —CH═CH—C≡C—;
      • (c) —C≡C—CH═CH—;
      • (d) —C≡C—C≡C—;
  • Figure US20170369426A1-20171228-C00014
  • and
      • (g) phenyl; and
  • D is selected from the group consisting of:
  • Figure US20170369426A1-20171228-C00015
      • wherein
        • Q is O or NR, wherein R is hydrogen or an unsubstituted C1-C3 alkyl;
        • R1 and R2 independently are selected from the group consisting of hydrogen, and substituted or unsubstituted C1-C3 alkyl, or R1 and R2, together with the carbon atom to which they are attached, form an unsubstituted C3-C6 cycloalkyl group or an unsubstituted 4-6 membered heterocyclic group; and
        • R3 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C6-alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl.
          In certain embodiments, A is substituted C1-C6 alkyl, wherein at least one substituent is hydroxy. In certain embodiments, A is substituted C1-C6 alkyl, wherein at least two substituents are hydroxy. For example, in certain embodiments A is hydroxymethyl, hydroxyethyl, hydroxypropyl or dihydroxypropyl.
  • In other embodiments, A is substituted C3-C6 cycloalkyl, wherein at least one substituent is selected from hydroxy and hydroxyalkyl. In certain embodiments, A is substituted C3-C6 cycloalkyl, wherein at least one substituent is hydroxymethyl. For example, in certain embodiments A is hydroxymethylcyclopropyl. In other embodiments, A is substituted C3-C6 cycloalkyl, wherein at least one substituent is hydroxy.
  • In certain embodiments, G is —C≡C—C≡C—.
    In certain embodiments of compounds of Formula I, D is
  • Figure US20170369426A1-20171228-C00016
  • wherein W is N or N+—O−. In other embodiments of compounds of Formula I, D is
  • Figure US20170369426A1-20171228-C00017
  • In still other embodiments of compounds of Formula I, D is
  • Figure US20170369426A1-20171228-C00018
  • Finally, in still other embodiments of compounds of Formula I, D is
  • Figure US20170369426A1-20171228-C00019
  • In certain embodiments, R1 is hydrogen. Similarly, in certain embodiments, R2 is hydrogen. In certain embodiments of compounds of Formula I, E is —C(CH3)2SCH3. In other embodiments, E is —C(CH3)2S(O)2CH3. In still other embodiments, E is —C(CH3)2S(O)CH3. In still other embodiments, E is —C(O)NHCH3.
    The compounds of the invention include the compounds of Table I below.
  • TABLE I
    # structure name
     1
    Figure US20170369426A1-20171228-C00020
         		N-hydroxy-2-(4-(((trans)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)phenyl)-1,6-naphthyridine-4- carboxamide
     2
    Figure US20170369426A1-20171228-C00021
         		N-hydroxy-4-(4-(((trans)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)phenyl)picolinamide
     3
    Figure US20170369426A1-20171228-C00022
         		N-((R)-1-(hydroxyamino)-3-methyl-3- (methylthio)-1-oxobutan-2-yl)-4-(((trans)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)benzamide
     4
    Figure US20170369426A1-20171228-C00023
         		N-((2R)-1-(hydroxyamino)-3-methyl-3- (methylsulfinyl)-1-oxobutan-2-yl)-4- (((trans)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)benzamide
     5
    Figure US20170369426A1-20171228-C00024
         		N-((R)-1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2-yl)-4- (((trans)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)benzamide
     6
    Figure US20170369426A1-20171228-C00025
         		N-((S)-3-amino-1-(hydroxyamino)-3- methyl-1-oxobutan-2-yl)-6-(((trans)-2- (hydroxymethyl)cyclopropyl)ethynyl)-2- naphthamide
     7
    Figure US20170369426A1-20171228-C00026
         		N-((S)-3-amino-1-(hydroxyamino)-3- methyl-1-oxobutan-2-yl)-6-(((trans)-2- (hydroxymethyl)cyclopropyl)ethynyl)benzo [b]thiophene-2-carboxamide
     8
    Figure US20170369426A1-20171228-C00027
         		N1-hydroxy-2-(4-(((1R,2R)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)benzamido)-N3-methylmalonamide
     9
    Figure US20170369426A1-20171228-C00028
         		N-hydroxy-4-(4-(((trans)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
     10
    Figure US20170369426A1-20171228-C00029
         		N-hydroxy-2-(4-(6-hydroxyhexa-1,3- diynyl)phenyl)-1,6-naphthyridine-4- carboxamide
     11
    Figure US20170369426A1-20171228-C00030
         		N-hydroxy-2-(4-(5-hydroxypenta-1,3- diynyl)phenyl)-1,6-naphthyridine-4- carboxamide
     12
    Figure US20170369426A1-20171228-C00031
         		N-hydroxy-2-(4-(5-hydroxyhexa-1,3- diynyl)phenyl)-1,6-naphthyridine-4- carboxamide
     13
    Figure US20170369426A1-20171228-C00032
         		N-hydroxy-2-(4-(6-hydroxy-5-methylhexa- 1,3-diynyl)phenyl)-1,6-naphthyridine-4- carboxamide
     14
    Figure US20170369426A1-20171228-C00033
         		2-(4-(5,6-dihydroxyhexa-1,3- diynyl)phenyl)-N-hydroxy-1,6- naphthyridine-4-carboxamide
     15
    Figure US20170369426A1-20171228-C00034
         		2-(4-(6,7-dihydroxyhepta-1,3- diynyl)phenyl)-N-hydroxy-1,6- naphthyridine-4-carboxamide
     16
    Figure US20170369426A1-20171228-C00035
         		N-hydroxy-2-(4-((3- (hydroxymethyl)cyclobutyl)buta-1,3- diynyl)phenyl)-1,6-naphthyridine-4- carboxamide
     17
    Figure US20170369426A1-20171228-C00036
         		N-hydroxy-2-(4-((3- (hydroxymethyl)cyclobutyl)buta-1,3- diynyl)phenyl)-1,6-naphthyridine-4- carboxamide
     18
    Figure US20170369426A1-20171228-C00037
         		N-hydroxy-2-(4-((3- hydroxycyclobutyl)buta-1,3-diynyl)phenyl)- 1,6-naphthyridine-4-carboxamide
     19
    Figure US20170369426A1-20171228-C00038
         		N-hydroxy-2-(4-((3- (hydroxymethyl)cyclopentyl)buta-1,3- diynyl)phenyl)-1,6-naphthyridine-4- carboxamide
     20
    Figure US20170369426A1-20171228-C00039
         		N-hydroxy-2-(4-(((1R,2S)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)phenyl)-1,6-naphthyridine-4- carboxamide
     21
    Figure US20170369426A1-20171228-C00040
         		N-hydroxy-2-(4-(6-hydroxy-5- methoxyhexa-1,3-diynyl)phenyl)-1,6- naphthyridine-4-carboxamide
     22
    Figure US20170369426A1-20171228-C00041
         		N-hydroxy-2-(4-(7-hydroxy-6- methoxyhepta-1,3-diynyl)phenyl)-1,6- naphthyridine-4-carboxamide
     23
    Figure US20170369426A1-20171228-C00042
         		4-(hydroxycarbamoyl)-2-(4-(6- hydroxyhexa-1,3-diynyl)phenyl)-1,6- naphthyridine 6-oxide
     24
    Figure US20170369426A1-20171228-C00043
         		4-(hydroxycarbamoyl)-2-(4-(5- hydroxypenta-1,3-diynyl)phenyl)-1,6- naphthyridine 6-oxide
     25
    Figure US20170369426A1-20171228-C00044
         		4-(hydroxycarbamoyl)-2-(4-(5- hydroxyhexa-1,3-diynyl)phenyl)-1,6- naphthyridine 6-oxide
     26
    Figure US20170369426A1-20171228-C00045
         		2-(4-(6-hydroxy-5-methylhexa-1,3- diynyl)phenyl)-4-(hydroxycarbamoyl)-1,6- naphthyridine 6-oxide
     27
    Figure US20170369426A1-20171228-C00046
         		2-(4-(5,6-dihydroxyhexa-1,3- diynyl)phenyl)-4-(hydroxycarbamoyl)-1,6- naphthyridine 6-oxide
     28
    Figure US20170369426A1-20171228-C00047
         		2-(4-(6,7-dihydroxyhepta-1,3- diynyl)phenyl)-4-(hydroxycarbamoyl)-1,6- naphthyridine 6-oxide
     29
    Figure US20170369426A1-20171228-C00048
         		4-(hydroxycarbamoyl)-2-(4-((3- (hydroxymethyl)cyclobutyl)buta-1,3- diynyl)phenyl)-1,6-naphthyridine 6-oxide
     30
    Figure US20170369426A1-20171228-C00049
         		4-(hydroxycarbamoyl)-2-(4-((3- hydroxycyclobutyl)buta-1,3-diynyl)phenyl)- 1,6-naphthyridine 6-oxide
     31
    Figure US20170369426A1-20171228-C00050
         		4-(hydroxycarbamoyl)-2-(4-((3- (hydroxymethyl)cyclopentyl)buta-1,3- diynyl)phenyl)-1,6-naphthyridine 6-oxide
     32
    Figure US20170369426A1-20171228-C00051
         		4-(hydroxycarbamoyl)-2-(4-(((1R,2S)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)phenyl)-1,6-naphthyridine 6-oxide
     33
    Figure US20170369426A1-20171228-C00052
         		2-(4-(6-hydroxy-5-methoxyhexa-1,3- diynyl)phenyl)-4-(hydroxycarbamoyl)-1,6- naphthyridine 6-oxide
     34
    Figure US20170369426A1-20171228-C00053
         		2-(4-(7-hydroxy-6-methoxyhepta-1,3- diynyl)phenyl)-4-(hydroxycarbamoyl)-1,6- naphthyridine 6-oxide
     35
    Figure US20170369426A1-20171228-C00054
         		N-hydroxy-4-(4-(((1S,2S)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     36
    Figure US20170369426A1-20171228-C00055
         		N-hydroxy-4-(4-(((1R,2R)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     37
    Figure US20170369426A1-20171228-C00056
         		N-hydroxy-4-(4-(((1R,2S)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     38
    Figure US20170369426A1-20171228-C00057
         		N-hydroxy-4-(4-(((1S,2R)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     39
    Figure US20170369426A1-20171228-C00058
         		N-hydroxy-4-(4-(5-hydroxypenta-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     40
    Figure US20170369426A1-20171228-C00059
         		N-hydroxy-4-(4-(6-hydroxyhexa-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     41
    Figure US20170369426A1-20171228-C00060
         		N-hydroxy-4-(4-(5-hydroxyhexa-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     42
    Figure US20170369426A1-20171228-C00061
         		N-hydroxy-4-(4-(6-hydroxy-5-methylhexa- 1,3-diynyl)-2-oxopyridin-1(2H)-yl)-2- methyl-2-(methylsulfonyl)butanamide
     43
    Figure US20170369426A1-20171228-C00062
         		4-(4-(5,6-dihydroxyhexa-1,3-diynyl)-2- oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl- 2-(methylsulfonyl)butanamide
     44
    Figure US20170369426A1-20171228-C00063
         		4-(4-(6,7-dihydroxyhepta-1,3-diynyl)-2- oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl- 2-(methylsulfonyl)butanamide
     45
    Figure US20170369426A1-20171228-C00064
         		N-hydroxy-4-(4-((3- hydroxycyclobutyl)buta-1,3-diynyl)-2- oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     46
    Figure US20170369426A1-20171228-C00065
         		N-hydroxy-4-(4-((3- (hydroxymethyl)cyclobutyl)buta-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     47
    Figure US20170369426A1-20171228-C00066
         		N-hydroxy-4-(4-((3- (hydroxymethyl)cyclopentyl)buta-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     48
    Figure US20170369426A1-20171228-C00067
         		N-hydroxy-4-(4-(6-hydroxy-5- methoxyhexa-1,3-diynyl)-2-oxopyridin- 1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     49
    Figure US20170369426A1-20171228-C00068
         		N-hydroxy-4-(4-(7-hydroxy-6- methoxyhepta-1,3-diynyl)-2-oxopyridin- 1(2H)-yl)-2-methyl-2- (methylsulfonyl)bulanamide
     50
    Figure US20170369426A1-20171228-C00069
         		N-hydroxy-4-(4-(6-hydroxyhexa-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     51
    Figure US20170369426A1-20171228-C00070
         		N-hydroxy-4-(4-(4-(((1S,2S)-2- (hydroxymethyl)cyclopropyl)ethynyl) phenyl)-2-oxopyridin-1(2H)-yl)-2- methyl-2-(methylsulfonyl)butanamide
     52
    Figure US20170369426A1-20171228-C00071
         		N-hydroxy-4-(4-(4-(((1R,2R)-2- (hydroxymethyl)cyclopropyl)ethynyl) phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl- 2-(methylsulfonyl)butanamide
     53
    Figure US20170369426A1-20171228-C00072
         		N-hydroxy-4-(4-(4-(((1R,2S)-2- (hydroxymethyl)cyclopropyl)ethynyl) phenyl)-2-oxopyridin-1(2H)-yl)-2- methyl-2-(methylsulfonyl)butanamide
     54
    Figure US20170369426A1-20171228-C00073
         		N-hydroxy-4-(4-(4-(((1S,2R)-2- (hydroxymethyl)cyclopropyl)ethynyl) phenyl)-2-oxopyridin-1(2H)-yl)-2- methyl-2-(methylsulfonyl)butanamide
     55
    Figure US20170369426A1-20171228-C00074
         		N-hydroxy-4-(4-(4-(3-hydroxyprop-1- ynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2- methyl-2-(methylsulfonyl)butanamide
     56
    Figure US20170369426A1-20171228-C00075
         		N-hydroxy-4-(4-(4-(4-hydroxybut-1- ynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2- methyl-2-(methylsulfonyl)butanamide
     57
    Figure US20170369426A1-20171228-C00076
         		N-hydroxy-4-(4-(4-(3-hydroxybut-1- ynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2- methyl-2-(methylsulfonyl)butanamide
     58
    Figure US20170369426A1-20171228-C00077
         		N-hydroxy-4-(4-(4-(4-hydroxy-3-methylbut- 1-ynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2- methyl-2-(methylsulfonyl)butanamide
     59
    Figure US20170369426A1-20171228-C00078
         		4-(4-(4-(3,4-dihydroxybut-1-ynyl)phenyl)- 2-oxopyridin-1(2H)-yl)-N-hydroxy-2- methyl-2-(methylsulfonyl)butanamide
     60
    Figure US20170369426A1-20171228-C00079
         		4-(4-(4-(4,5-dihydroxypent-1-ynyl)phenyl)- 2-oxopyridin-1(2H)-yl)-N-hydroxy-2- methyl-2-(methylsulfonyl)butanamide
     61
    Figure US20170369426A1-20171228-C00080
         		N-hydroxy-4-(4-(4-((3- hydroxycyclobutyl)ethynyl)phenyl)-2- oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     62
    Figure US20170369426A1-20171228-C00081
         		N-hydroxy-4-(4-(4-((3- (hydroxymethyl)cyclobutyl)ethynyl) phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     63
    Figure US20170369426A1-20171228-C00082
         		N-hydroxy-4-(4-(4-((3- (hydroxymethyl)cyclopentyl)ethynyl) phenyl)-2-oxopyridin-1(2H)-yl)-2- methyl-2-(methylsulfonyl)butanamide
     64
    Figure US20170369426A1-20171228-C00083
         		N-hydroxy-4-(4-(4-(4-hydroxy-3- methoxybut-1-ynyl)phenyl)-2-oxopyridin- 1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     65
    Figure US20170369426A1-20171228-C00084
         		N-hydroxy-4-(4-(4-(5-hydroxy-4- methoxypent-1-ynyl)phenyl)-2-oxopyridin- 1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     66
    Figure US20170369426A1-20171228-C00085
         		N-hydroxy-4-(4-(6-hydroxyhexa-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     67
    Figure US20170369426A1-20171228-C00086
         		N-hydroxy-4-(4-(4-((2S)-2- (hydroxymethyl)cyclopropyl)phenyl)-2- oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     68
    Figure US20170369426A1-20171228-C00087
         		N-hydroxy-4-(4-(4-((2R)-2- (hydroxymethyl)cyclopropyl)phenyl)-2- oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     69
    Figure US20170369426A1-20171228-C00088
         		N-hydroxy-4-(4-(4-((2S)-2- (hydroxymethyl)cyclopropyl)phenyl)-2- oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     70
    Figure US20170369426A1-20171228-C00089
         		N-hydroxy-4-(4-(4-((2R)-2- (hydroxymethyl)cyclopropyl)phenyl)-2- oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     71
    Figure US20170369426A1-20171228-C00090
         		N-hydroxy-4-(4-(4- (hydroxymethyl)phenyl)-2-oxopyridin- 1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     72
    Figure US20170369426A1-20171228-C00091
         		N-hydroxy-4-(4-(4-(2- hydroxyethyl)phenyl)-2-oxopyridin-1(2H)- yl)-2-methyl-2-(methylsulfonyl)butanamide
     73
    Figure US20170369426A1-20171228-C00092
         		N-hydroxy-4-(4-(4-(1- hydroxyethyl)phenyl)-2-oxopyridin-1(2H)- yl)-2-methyl-2-(methylsulfonyl)butanamide
     74
    Figure US20170369426A1-20171228-C00093
         		N-hydroxy-4-(4-(4-(1-hydroxypropan-2- yl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl- 2-(methyisulfonyl)butanamide
     75
    Figure US20170369426A1-20171228-C00094
         		4-(4-(4-(1,2-dihydroxyethyl)phenyl)-2- oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl- 2-(methylsulfonyl)butanamide
     76
    Figure US20170369426A1-20171228-C00095
         		4-(4-(4-(2,3-dihydroxypropyl)phenyl)-2- oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl- 2-(methylsulfonyl)butanamide
     77
    Figure US20170369426A1-20171228-C00096
         		N-hydroxy-4-(4-(4-(3- hydroxycyclobutyl)phenyl)-2-oxopyridin- 1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     78
    Figure US20170369426A1-20171228-C00097
         		N-hydroxy-4-(4-(4-(3- (hydroxymethyl)cyclobutyl)phenyl)-2- oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     79
    Figure US20170369426A1-20171228-C00098
         		N-hydroxy-4-(4-(4-(3- (hydroxymethyl)cyclopentyl)phenyl)-2- oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     80
    Figure US20170369426A1-20171228-C00099
         		N-hydroxy-4-(4-(4-(2-hydroxy-1- methoxyethyl)phenyl)-2-oxopyridin-1(2H)- yl)-2-methyl-2-(methylsulfonyl)butanamide
     81
    Figure US20170369426A1-20171228-C00100
         		N-hydroxy-4-(4-(4-(3-hydroxy-2- methoxypropyl)phenyl)-2-oxopyridin- 1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     82
    Figure US20170369426A1-20171228-C00101
         		N-hydroxy-4-(4-(6-hydroxyhexa-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     83
    Figure US20170369426A1-20171228-C00102
         		N-hydroxy-4-(4-(4-((E)-2-((1R,2S)-2- (hydroxymethyl)cyclopropyl)vinyl)phenyl)- 2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     84
    Figure US20170369426A1-20171228-C00103
         		N-hydroxy-4-(4-(4-((E)-2-((1S,2R)-2- (hydroxymethyl)cyclopropyl)vinyl)phenyl)- 2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     85
    Figure US20170369426A1-20171228-C00104
         		N-hydroxy-4-(4-(4-((E)-2-((1S,2S)-2- (hydroxymethyl)cyclopropyl)vinyl)phenyl)- 2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     86
    Figure US20170369426A1-20171228-C00105
         		N-hydroxy-4-(4-(4-((E)-2-((1R,2R)-2- (hydroxymethyl)cyclopropyl)vinyl)phenyl)- 2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     87
    Figure US20170369426A1-20171228-C00106
         		(E)-N-hydroxy-4-(4-(4-(3-hydroxyprop-1- enyl)phenyl)-2-oxopyridin-1(2H)-yl)-2- methyl-2-(methylsulfonyl)butanamide
     88
    Figure US20170369426A1-20171228-C00107
         		(E)-N-hydroxy-4-(4-(4-(4-hydroxybut-1- enyl)phenyl)-2-oxopyridin-1(2H)-yl)-2- methyl-2-(methylsulfonyl)butanamide
     89
    Figure US20170369426A1-20171228-C00108
         		(E)-N-hydroxy-4-(4-(4-(3-hydroxybut-1- enyl)phenyl)-2-oxopyridin-1(2H)-yl)-2- methyl-2-(methylsulfonyl)butanamide
     90
    Figure US20170369426A1-20171228-C00109
         		(E)-N-hydroxy-4-(4-(4-(4-hydroxy-3- methylbut-1-enyl)phenyl)-2-oxopyridin- 1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     91
    Figure US20170369426A1-20171228-C00110
         		(E)-4-(4-(4-(3,4-dihydroxybut-1- enyl)phenyl)-2-oxopyridin-1(2H)-yl)-N- hydroxy-2-methyl-2- (methylsulfonyl)butanamide
     92
    Figure US20170369426A1-20171228-C00111
         		(E)-4-(4-(4-(4,5-dihydroxypent-1- enyl)phenyl)-2-oxopyridin-1(2H)-yl)-N- hydroxy-2-methyl-2- (methylsulfonyl)butanamide
     93
    Figure US20170369426A1-20171228-C00112
         		(E)-N-hydroxy-4-(4-(4-(2-(3- hydroxycyclobutyl)vinyl)phenyl)-2- oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     94
    Figure US20170369426A1-20171228-C00113
         		(E)-N-hydroxy-4-(4-(4-(2-(3- (hydroxymethyl)cyclobutyl)vinyl)phenyl)-2- oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     95
    Figure US20170369426A1-20171228-C00114
         		(E)-N-hydroxy-4-(4-(4-(2-(3- (hydroxymethyl)cyclopentyl)vinyl)phenyl)- 2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     96
    Figure US20170369426A1-20171228-C00115
         		(E)-N-hydroxy-4-(4-(4-(4-hydroxy-3- methoxybut-1-enyl)phenyl)-2-oxopyridin- 1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     97
    Figure US20170369426A1-20171228-C00116
         		(E)-N-hydroxy-4-(4-(4-(5-hydroxy-4- methoxypent-1-enyl)phenyl)-2-oxopyridin- 1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     98
    Figure US20170369426A1-20171228-C00117
         		N-hydroxy-4-(4-(6-hydroxyhexa-1,3- diynyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
     99
    Figure US20170369426A1-20171228-C00118
         		N-hydroxy-4-(4-(((1S,2S)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
    100
    Figure US20170369426A1-20171228-C00119
         		N-hydroxy-4-(4-(((1R,2R)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
    101
    Figure US20170369426A1-20171228-C00120
         		N-hydroxy-4-(4-(((1R,2S)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
    102
    Figure US20170369426A1-20171228-C00121
         		N-hydroxy-4-(4-(((1S,2R)-2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
    103
    Figure US20170369426A1-20171228-C00122
         		N-hydroxy-4-(4-(5-hydroxypenta-1,3- diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
    104
    Figure US20170369426A1-20171228-C00123
         		N-hydroxy-4-(4-(6-hydroxyhexa-1,3- diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
    105
    Figure US20170369426A1-20171228-C00124
         		N-hydroxy-4-(4-(5-hydroxyhexa-1,3- diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
    106
    Figure US20170369426A1-20171228-C00125
         		N-hydroxy-4-(4-(6-hydroxy-5-methylhexa- 1,3-diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
    107
    Figure US20170369426A1-20171228-C00126
         		4-(4-(5,6-dihydroxyhexa-1,3- diynyl)phenyl)-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamide
    108
    Figure US20170369426A1-20171228-C00127
         		4-(4-(6,7-dihydroxyhepta-1,3- diynyl)phenyl)-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamide
    109
    Figure US20170369426A1-20171228-C00128
         		N-hydroxy-4-(4-((3- hydroxycyclobutyl)buta-1,3-diynyl)phenyl)- 2-methyl-2-(methylsulfonyl)butanamide
    110
    Figure US20170369426A1-20171228-C00129
         		N-hydroxy-4-(4-((3- (hydroxymethyl)cyclobutyl)buta-1,3- diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
    111
    Figure US20170369426A1-20171228-C00130
         		N-hydroxy-4-(4-((3- (hydroxymethyl)cyclopentyl)buta-1,3- diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
    112
    Figure US20170369426A1-20171228-C00131
         		N-hydroxy-4-(4-(6-hydroxy-5- methoxyhexa-1,3-diynyl)phenyl)-2-methyl- 2-(methylsulfonyl)butanamide
    113
    Figure US20170369426A1-20171228-C00132
         		N-hydroxy-4-(4-(7-hydroxy-6- methoxyhepta-1,3-diynyl)phenyl)-2- methyl-2-(methylsulfonyl)butanamide
    114
    Figure US20170369426A1-20171228-C00133
         		N-hydroxy-4-(4-(6-hydroxyhexa-1,3- diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
    115
    Figure US20170369426A1-20171228-C00134
         		N-hydroxy-4-(4′-(((1S,2S)-2- (hydroxymethyl)cyclopropyl)ethynyl) biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    116
    Figure US20170369426A1-20171228-C00135
         		N-hydroxy-4-(4′-(((1R,2R)-2- (hydroxymethyl)cyclopropyl)ethynyl) biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    117
    Figure US20170369426A1-20171228-C00136
         		N-hydroxy-4-(4′-(((1R,2S)-2- (hydroxymethyl)cyclopropyl)ethynyl) biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    118
    Figure US20170369426A1-20171228-C00137
         		N-hydroxy-4-(4′-(((1S,2R)-2- (hydroxymethyl)cyclopropyl)ethynyl) biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    119
    Figure US20170369426A1-20171228-C00138
         		N-hydroxy-4-(4′-(3-hydroxyprop-1- ynyl)biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    120
    Figure US20170369426A1-20171228-C00139
         		N-hydroxy-4-(4′-(4-hydroxybut-1- ynyl)biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    121
    Figure US20170369426A1-20171228-C00140
         		N-hydroxy-4-(4′-(3-hydroxybut-1- ynyl)biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    122
    Figure US20170369426A1-20171228-C00141
         		N-hydroxy-4-(4′-(4-hydroxy-3-methylbut-1- ynyl)biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    123
    Figure US20170369426A1-20171228-C00142
         		4-(4′-(3,4-dihydroxybut-1-ynyl)biphenyl-4- yl)-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamide
    124
    Figure US20170369426A1-20171228-C00143
         		4-(4′-(4,5-dihydroxypent-1-ynyl)biphenyl-4- yl)-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamide
    125
    Figure US20170369426A1-20171228-C00144
         		N-hydroxy-4-(4′-((3- hydroxycyclobutyl)ethynyl)biphenyl-4-yl)- 2-methyl-2-(methylsulfonyl)butanamide
    126
    Figure US20170369426A1-20171228-C00145
         		N-hydroxy-4-(4′-((3- (hydroxymethyl)cyclobutyl)ethynyl) biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    127
    Figure US20170369426A1-20171228-C00146
         		N-hydroxy-4-(4′-((3- (hydroxymethyl)cyclopentyl)ethynyl) biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    128
    Figure US20170369426A1-20171228-C00147
         		N-hydroxy-4-(4′-(4-hydroxy-3-methoxybut- 1-ynyl)biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    129
    Figure US20170369426A1-20171228-C00148
         		N-hydroxy-4-(4′-(5-hydroxy-4- methoxypent-1-ynyl)biphenyl-4-yl)-2- methyl-2-(methylsulfonyl)butanamide
    130
    Figure US20170369426A1-20171228-C00149
         		N-hydroxy-4-(4-(6-hydroxyhexa-1,3- diynyl)phenyl)-2-methyl-2- (methylsulfonyl)butanamide
    131
    Figure US20170369426A1-20171228-C00150
         		N-hydroxy-4-(4′-((2S)-2- (hydroxymethyl)cyclopropyl)biphenyl-4-yl)- 2-methyl-2-(methylsulfonyl)butanamide
    132
    Figure US20170369426A1-20171228-C00151
         		N-hydroxy-4-(4′-((2R)-2- (hydroxymethyl)cyclopropyl)biphenyl-4-yl)- 2-methyl-2-(methylsulfonyl)butanamide
    133
    Figure US20170369426A1-20171228-C00152
         		N-hydroxy-4-(4′-((2S)-2- (hydroxymethyl)cyclopropyl)biphenyl-4-yl)- 2-methyl-2-(methylsulfonyl)butanamide
    134
    Figure US20170369426A1-20171228-C00153
         		N-hydroxy-4-(4′-((2R)-2- (hydroxymethyl)cyclopropyl)biphenyl-4-yl)- 2-methyl-2-(methylsulfonyl)butanamide
    135
    Figure US20170369426A1-20171228-C00154
         		N-hydroxy-4-(4′-(hydroxymethyl)biphenyl- 4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    136
    Figure US20170369426A1-20171228-C00155
         		N-hydroxy-4-(4′-(2-hydroxyethyl)biphenyl- 4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    137
    Figure US20170369426A1-20171228-C00156
         		N-hydroxy-4-(4′-(1-hydroxyethyl)biphenyl- 4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    138
    Figure US20170369426A1-20171228-C00157
         		N-hydroxy-4-(4′-(1-hydroxypropan-2- yl)biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    139
    Figure US20170369426A1-20171228-C00158
         		4-(4′-(1,2-dihydroxyethyl)biphenyl-4-yl)-N- hydroxy-2-methyl-2- (methylsulfonyl)butanamide
    140
    Figure US20170369426A1-20171228-C00159
         		4-(4′-(2,3-dihydroxypropyl)biphenyl-4-yl)- N-hydroxy-2-methyl-2- (methylsulfonyl)butanamide
    141
    Figure US20170369426A1-20171228-C00160
         		N-hydroxy-4-(4′-(3- hydroxycyclobutyl)biphenyl-4-yl)-2-methyl- 2-(methylsulfonyl)butanamide
    142
    Figure US20170369426A1-20171228-C00161
         		N-hydroxy-4-(4′-(3- (hydroxymethyl)cyclobutyl)biphenyl-4-yl)- 2-methyl-2-(methylsulfonyl)butanamide
    143
    Figure US20170369426A1-20171228-C00162
         		N-hydroxy-4-(4′-(3- (hydroxymethyl)cyclopentyl)biphenyl-4-yl)- 2-methyl-2-(methylsulfonyl)butanamide
    144
    Figure US20170369426A1-20171228-C00163
         		N-hydroxy-4-(4′-(2-hydroxy-1- methoxyethyl)biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    145
    Figure US20170369426A1-20171228-C00164
         		N-hydroxy-4-(4′-(3-hydroxy-2- methoxypropyl)biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    146
    Figure US20170369426A1-20171228-C00165
         		N-hydroxy-4-(4′-((E)-2-((1R,2S)-2- (hydroxymethyl)cyclopropyl)vinyl)biphenyl- 4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    147
    Figure US20170369426A1-20171228-C00166
         		N-hydroxy-4-(4′-((E)-2-((1S,2R)-2- (hydroxymethyl)cyclopropyl)vinyl)biphenyl- 4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    148
    Figure US20170369426A1-20171228-C00167
         		N-hydroxy-4-(4′-((E)-2-((1S,2S)-2- (hydroxymethyl)cyclopropyl)vinyl)biphenyl- 4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    149
    Figure US20170369426A1-20171228-C00168
         		N-hydroxy-4-(4′-((E)-2-((1R,2R)-2- (hydroxymethyl)cyclopropyl)vinyl)biphenyl- 4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    150
    Figure US20170369426A1-20171228-C00169
         		(E)-N-hydroxy-4-(4′-(3-hydroxyprop-1- enyl)biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    151
    Figure US20170369426A1-20171228-C00170
         		(E)-N-hydroxy-4-(4′-(4-hydroxybut-1- enyl)biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    152
    Figure US20170369426A1-20171228-C00171
         		(E)-N-hydroxy-4-(4′-(3-hydroxybut-1- enyl)biphenyl-4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    153
    Figure US20170369426A1-20171228-C00172
         		(E)-N-hydroxy-4-(4′-(4-hydroxy-3- methylbut-1-enyl)biphenyl-4-yl)-2-methyl- 2-(methylsulfonyl)butanamide
    154
    Figure US20170369426A1-20171228-C00173
         		(E)-4-(4′-(3,4-dihydroxybut-1- enyl)biphenyl-4-yl)-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamide
    155
    Figure US20170369426A1-20171228-C00174
         		(E)-4-(4′-(4,5-dihydroxypent-1- enyl)biphenyl-4-yl)-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamide
    156
    Figure US20170369426A1-20171228-C00175
         		(E)-N-hydroxy-4-(4′-(2-(3- hydroxycyclobutyl)vinyl)biphenyl-4-yl)-2- methyl-2-(methylsulfonyl)butanamide
    157
    Figure US20170369426A1-20171228-C00176
         		(E)-N-hydroxy-4-(4′-(2-(3- (hydroxymethyl)cyclobutyl)vinyl)biphenyl- 4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    158
    Figure US20170369426A1-20171228-C00177
         		(E)-N-hydroxy-4-(4′-(2-(3- (hydroxymethyl)cyclopentyl)vinyl)biphenyl- 4-yl)-2-methyl-2- (methylsulfonyl)butanamide
    159
    Figure US20170369426A1-20171228-C00178
         		(E)-N-hydroxy-4-(4-(4-(4-hydroxy-3- methoxybut-1-enyl)phenyl)-2-oxopyridin- 1(2H)-yl)-2-methyl-2- (methylsulfonyl)butanamide
    160
    Figure US20170369426A1-20171228-C00179
         		(R)-N-(1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2-yl)-4-(5- hydroxypenta-1,3-diynyl)benzamide
    161
    Figure US20170369426A1-20171228-C00180
         		(R)-N-(1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2-yl)-4-(6- hydroxyhexa-1,3-diynyl)benzamide
    162
    Figure US20170369426A1-20171228-C00181
         		4-(5,6-dihydroxyhexa-1,3-diynyl)-N-((R)-1- (hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2- yl)benzamide
    163
    Figure US20170369426A1-20171228-C00182
         		4-(6,7-dihydroxyhepta-1,3-diynyl)-N-((R)- 1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2- yl)benzamide
    164
    Figure US20170369426A1-20171228-C00183
         		4-(6-hydroxy-5-methylhexa-1,3-diynyl)-N- ((R)-1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2- yl)benzamide
    165
    Figure US20170369426A1-20171228-C00184
         		(R)-N-(1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2-yl)-4-((3- hydroxycyclobutyl)buta-1,3- diynyl)benzamide
    166
    Figure US20170369426A1-20171228-C00185
         		(R)-N-(1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2-yl)-4-((3- (hydroxymethyl)cyclobutyl)buta-1,3- diynyl)benzamide
    167
    Figure US20170369426A1-20171228-C00186
         		N-((R)-1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2-yl)-4-((3- (hydroxymethyl)cyclopentyl)buta-1,3- diynyl)benzamide
    168
    Figure US20170369426A1-20171228-C00187
         		N-((R)-1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2-yl)-4-(5- hydroxyhexa-1,3-diynyl)benzamide
    169
    Figure US20170369426A1-20171228-C00188
         		4-(6-hydroxy-5-methoxyhexa-1,3-diynyl)- N-((R)-1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2- yl)benzamide
    170
    Figure US20170369426A1-20171228-C00189
         		4-(7-hydroxy-6-methoxyhepta-1,3-diynyl)- N-((R)-1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2- yl)benzamide
    171
    Figure US20170369426A1-20171228-C00190
         		N-((R)-1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2-yl)-4-((2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)benzamide
    172
    Figure US20170369426A1-20171228-C00191
         		N-((2R)-1-(hydroxyamino)-3-methyl-3- (methylsulfinyl)-1-oxobutan-2-yl)-4-(5- hydroxypenta-1,3-diynyl)benzamide
    173
    Figure US20170369426A1-20171228-C00192
         		N-((2R)-1-(hydroxyamino)-3-methyl-3- (methylsulfinyl)-1-oxobutan-2-yl)-4-(6- hydroxyhexa-1,3-diynyl)benzamide
    174
    Figure US20170369426A1-20171228-C00193
         		4-(5,6-dihydroxyhexa-1,3-diynyl)-N-((2R)- 1-(hydroxyamino)-3-methyl-3- (methylsulfinyl)-1-oxobutan-2- yl)benzamide
    175
    Figure US20170369426A1-20171228-C00194
         		4-(6,7-dihydroxyhepta-1,3-diynyl)-N-((2R)- 1-(hydroxyamino)-3-methyl-3- (methylsulfinyl)-1-oxobutan-2- yl)benzamide
    176
    Figure US20170369426A1-20171228-C00195
         		4-(6-hydroxy-5-methylhexa-1,3-diynyl)-N- ((R)-1-(hydroxyamino)-3-methyl-3- (methylsulfonyl)-1-oxobutan-2- yl)benzamide
    177
    Figure US20170369426A1-20171228-C00196
         		N-((2R)-1-(hydroxyamino)-3-methyl-3- (methylsulfinyl)-1-oxobutan-2-yl)-4-((3- hydroxycyclobutyl)buta-1,3- diynyl)benzamide
    178
    Figure US20170369426A1-20171228-C00197
         		N-((2R)-1-(hydroxyamino)-3-methyl-3- (methylsulfinyl)-1-oxobutan-2-yl)-4-((3- (hydroxymethyl)cyclobutyl)buta-1,3- diynyl)benzamide
    179
    Figure US20170369426A1-20171228-C00198
         		N-((2R)-1-(hydroxyamino)-3-methyl-3- (methylsulfinyl)-1-oxobutan-2-yl)-4-((3- (hydroxymethyl)cyclopentyl)buta-1,3- diynyl)benzamide
    180
    Figure US20170369426A1-20171228-C00199
         		N-((2R)-1-(hydroxyamino)-3-methyl-3- (methylsulfinyl)-1-oxobutan-2-yl)-4-(5- hydroxyhexa-1,3-diynyl)benzamide
    181
    Figure US20170369426A1-20171228-C00200
         		4-(6-hydroxy-5-methoxyhexa-1,3-diynyl)- N-((2R)-1-(hydroxyamino)-3-methyl-3- (methylsulfinyl)-1-oxobutan-2- yl)benzamide
    182
    Figure US20170369426A1-20171228-C00201
         		4-(7-hydroxy-6-methoxyhepta-1,3-diynyl)- N-((2R)-1-(hydroxyamino)-3-methyl-3- (methylsulfinyl)-1-oxobutan-2- yl)benzamide
    183
    Figure US20170369426A1-20171228-C00202
         		N-((2R)-1-(hydroxyamino)-3-methyl-3- (methylsulfinyl)-1-oxobutan-2-yl)-4-((2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)benzamide
    184
    Figure US20170369426A1-20171228-C00203
         		N-((R)-1-(hydroxyamino)-3-methyl-3- (methylthio)-1-oxobutan-2-yl)-4-((2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)benzamide
    185
    Figure US20170369426A1-20171228-C00204
         		(R)-N-(1-(hydroxyamino)-3-methyl-3- (methylthio)-1-oxobutan-2-yl)-4-(5- hydroxypenta-1,3-diynyl)benzamide
    186
    Figure US20170369426A1-20171228-C00205
         		(R)-N-(1-(hydroxyamino)-3-methyl-3- (methylthio)-1-oxobutan-2-yl)-4-(6- hydroxyhexa-1,3-diynyl)benzamide
    187
    Figure US20170369426A1-20171228-C00206
         		4-(5,6-dihydroxyhexa-1,3-diynyl)-N-((R)-1- (hydroxyamino)-3-methyl-3-(methylthio)-1- oxobutan-2-yl)benzamide
    188
    Figure US20170369426A1-20171228-C00207
         		4-(6,7-dihydroxyhepta-1,3-diynyl)-N-((R)- 1-(hydroxyamino)-3-methyl-3-(methylthio)- 1-oxobutan-2-yl)benzamide
    189
    Figure US20170369426A1-20171228-C00208
         		4-(6-hydroxy-5-methylhexa-1,3-diynyl)-N- ((R)-1-(hydroxyamino)-3-methyl-3- (methylthio)-1-oxobutan-2-yl)benzamide
    190
    Figure US20170369426A1-20171228-C00209
         		(R)-N-(1-(hydroxyamino)-3-methyl-3- (methylthio)-1-oxobutan-2-yl)-4-((3- hydroxycyclobutyl)buta-1,3- diynyl)benzamide
    191
    Figure US20170369426A1-20171228-C00210
         		(R)-N-(1-(hydroxyamino)-3-methyl-3- (methylthio)-1-oxobutan-2-yl)-4-((3- (hydroxymethyl)cyclobutyl)buta-1,3- diynyl)benzamide
    192
    Figure US20170369426A1-20171228-C00211
         		N-((R)-1-(hydroxyamino)-3-methyl-3- (methylthio)-1-oxobutan-2-yl)-4-((3- (hydroxymethyl)cyclopentyl)buta-1,3- diynyl)benzamide
    193
    Figure US20170369426A1-20171228-C00212
         		N-((R)-1-(hydroxyamino)-3-methyl-3- (methylthio)-1-oxobutan-2-yl)-4-(5- hydroxyhexa-1,3-diynyl)benzamide
    194
    Figure US20170369426A1-20171228-C00213
         		4-(6-hydroxy-5-methoxyhexa-1,3-diynyl)- N-((R)-1-(hydroxyamino)-3-methyl-3- (methylthio)-1-oxobutan-2-yl)benzamide
    195
    Figure US20170369426A1-20171228-C00214
         		4-(7-hydroxy-6-methoxyhepta-1,3-diynyl)- N-((R)-1-(hydroxyamino)-3-methyl-3- (methylthio)-1-oxobutan-2-yl)benzamide
    196
    Figure US20170369426A1-20171228-C00215
         		N-((R)-1-(hydroxyamino)-3-methyl-3- (methylthio)-1-oxobutan-2-yl)-4-((2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)benzamide
    197
    Figure US20170369426A1-20171228-C00216
         		N1-hydroxy-2-(4-((2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)benzamido)-N3-methylmalonamide
    198
    Figure US20170369426A1-20171228-C00217
         		N1-hydroxy-2-(4-(5-hydroxypenta-1,3- diynyl)benzamido)-N3-methylmalonamide
    199
    Figure US20170369426A1-20171228-C00218
         		N1-hydroxy-2-(4-(6-hydroxyhexa-1,3- diynyl)benzamido)-N3-methylmalonamide
    200
    Figure US20170369426A1-20171228-C00219
         		N1-hydroxy-2-(4-(5-hydroxyhexa-1,3- diynyl)benzamido)-N3-methylmalonamide
    201
    Figure US20170369426A1-20171228-C00220
         		2-(4-(5,6-dihydroxyhexa-1,3- diynyl)benzamido)-N1-hydroxy-N3- methylmalonamide
    202
    Figure US20170369426A1-20171228-C00221
         		2-(4-(6,7-dihydroxyhepta-1,3- diynyl)benzamido)-N1-hydroxy-N3- methylmalonamide
    203
    Figure US20170369426A1-20171228-C00222
         		N1-hydroxy-2-(4-(6-hydroxy-5- methylhexa-1,3-diynyl)benzamido)-N3- methylmalonamide
    204
    Figure US20170369426A1-20171228-C00223
         		N1-hydroxy-2-(4-((3- hydroxycyclobutyl)buta-1,3- diynyl)benzamido)-N3-methylmalonamide
    205
    Figure US20170369426A1-20171228-C00224
         		N1-hydroxy-2-(4-((3- (hydroxymethyl)cyclobutyl)buta-1,3- diynyl)benzamido)-N3-methylmalonamide
    206
    Figure US20170369426A1-20171228-C00225
         		N1-hydroxy-2-(4-((3- (hydroxymethyl)cyclopentyl)buta-1,3- diynyl)benzamido)-N3-methylmalonamide
    207
    Figure US20170369426A1-20171228-C00226
         		N1-hydroxy-2-(4-(6-hydroxy-5- methoxyhexa-1,3-diynyl)benzamido)-N3- methylmalonamide
    208
    Figure US20170369426A1-20171228-C00227
         		N1-hydroxy-2-(4-(7-hydroxy-6- methoxyhepta-1,3-diynyl)benzamido)-N3- methylmalonamide
    209
    Figure US20170369426A1-20171228-C00228
         		N1-hydroxy-2-(4-((2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)-N-methylbenzamido)-N3- methylmalonamide
    210
    Figure US20170369426A1-20171228-C00229
         		N1-hydroxy-2-(4-(5-hydroxypenta-1,3- diynyl)-N-methylbenzamido)-N3- methylmalonamide
    211
    Figure US20170369426A1-20171228-C00230
         		N1-hydroxy-2-(4-(6-hydroxyhexa-1,3- diynyl)-N-methylbenzamido)-N3- methylmalonamide
    217
    Figure US20170369426A1-20171228-C00231
         		N1-hydroxy-2-(4-(5-hydroxyhexa-1,3- diynyl)-N-methylbenzamido)-N3- methylmalonamide
    213
    Figure US20170369426A1-20171228-C00232
         		2-(4-(5,6-dihydroxyhexa-1,3-diynyl)-N- methylbenzamido)-N1-hydroxy-N3- methylmalonamide
    214
    Figure US20170369426A1-20171228-C00233
         		2-(4-(6,7-dihydroxyhepta-1,3-diynyl)-N- methylbenzamido)-N1-hydroxy-N3- methylmalonamide
    215
    Figure US20170369426A1-20171228-C00234
         		N1-hydroxy-2-(4-(6-hydroxy-5- methylhexa-1,3-diynyl)-N- methylbenzamido)-N3-methylmalonamide
    216
    Figure US20170369426A1-20171228-C00235
         		N1-hydroxy-2-(4-((3- hydroxycyclobutyl)buta-1,3-diynyl)-N- methylbenzamido)-N3-methylmalonamide
    217
    Figure US20170369426A1-20171228-C00236
         		N1-hydroxy-2-(4-((3- (hydroxymethyl)cyclobutyl)buta-1,3- diynyl)-N-methylbenzamido)-N3- methylmalonamide
    218
    Figure US20170369426A1-20171228-C00237
         		N1-hydroxy-2-(4-((3- (hydroxymethyl)cyclopentyl)buta-1,3- diynyl)-N-methylbenzamido)-N3- methylmalonamide
    219
    Figure US20170369426A1-20171228-C00238
         		N1-hydroxy-2-(4-(6-hydroxy-5- methoxyhexa-1,3-diynyl)-N- methylbenzamido)-N3-methylmalonamide
    220
    Figure US20170369426A1-20171228-C00239
         		N1-hydroxy-2-(4-(7-hydroxy-6- methoxyhepta-1,3-diynyl)-N- methylbenzamido)-N3-methylmalonamide
    221
    Figure US20170369426A1-20171228-C00240
         		N1-hydroxy-2-(4-((2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)benzamido)-N3,2- dimethylmalonamide
    222
    Figure US20170369426A1-20171228-C00241
         		N1-hydroxy-2-(4-(5-hydroxypenta-1,3- diynyl)benzamido)-N3,2- dimethylmalonamide
    223
    Figure US20170369426A1-20171228-C00242
         		N1-hydroxy-2-(4-(6-hydroxyhexa-1,3- diynyl)benzamido)-N3,2- dimethylmalonamide
    224
    Figure US20170369426A1-20171228-C00243
         		N1-hydroxy-2-(4-(5-hydroxyhexa-1,3- diynyl)benzamido)-N3,2- dimethylmalonamide
    225
    Figure US20170369426A1-20171228-C00244
         		2-(4-(5,6-dihydroxyhexa-1,3- diynyl)benzamido)-N1-hydroxy-N3,2- dimethylmalonamide
    226
    Figure US20170369426A1-20171228-C00245
         		2-(4-(6,7-dihydroxyhepta-1,3- diynyl)benzamido)-N1-hydroxy-N3,2- dimethylmalonamide
    227
    Figure US20170369426A1-20171228-C00246
         		N1-hydroxy-2-(4-(6-hydroxy-5- methylhexa-1,3-diynyl)benzamido)-N3,2- dimethylmalonamide
    228
    Figure US20170369426A1-20171228-C00247
         		N1-hydroxy-2-(4-((3- hydroxycyclobutyl)buta-1,3- diynyl)benzamido)-N3,2- dimethylmalonamide
    229
    Figure US20170369426A1-20171228-C00248
         		N1-hydroxy-2-(4-((3- (hydroxymethyl)cyclobutyl)buta-1,3- diynyl)benzamido)-N3,2- dimethylmalonamide
    230
    Figure US20170369426A1-20171228-C00249
         		N1-hydroxy-2-(4-((3- (hydroxymethyl)cyclopentyl)buta-1,3- diynyl)benzamido)-N3,2- dimethylmalonamide
    231
    Figure US20170369426A1-20171228-C00250
         		N1-hydroxy-2-(4-(6-hydroxy-5- methoxyhexa-1,3-diynyl)benzamido)- N3,2-dimethylmalonamide
    232
    Figure US20170369426A1-20171228-C00251
         		N1-hydroxy-2-(4-(7-hydroxy-6- methoxyhepta-1,3-diynyl)benzamido)- N3,2-dimethylmalonamide
    233
    Figure US20170369426A1-20171228-C00252
         		N1-hydroxy-2-(4-((2- (hydroxymethyl)cyclopropyl)buta-1,3- diynyl)-N-methylbenzamido)-N3,2- dimethylmalonamide
    234
    Figure US20170369426A1-20171228-C00253
         		N1-hydroxy-2-(4-(5-hydroxypenta-1,3- diynyl)-N-methylbenzamido)-N3,2- dimethylmalonamide
    235
    Figure US20170369426A1-20171228-C00254
         		N1-hydroxy-2-(4-(6-hydroxyhexa-1,3- diynyl)-N-methylbenzamido)-N3,2- dimethylmalonamide
    236
    Figure US20170369426A1-20171228-C00255
         		N1-hydroxy-2-(4-(5-hydroxyhexa-1,3- diynyl)-N-methylbenzamido)-N3,2- dimethylmalonamide
    237
    Figure US20170369426A1-20171228-C00256
         		2-(4-(5,6-dihydroxyhexa-1,3-diynyl)-N- methylbenzamido)-N7-hydroxy-N3,2- dimethylmalonamide
    238
    Figure US20170369426A1-20171228-C00257
         		2-(4-(6,7-dihydroxyhepta-1,3-diynyl)-N- methylbenzamido)-N1-hydroxy-N3,2- dimethylmalonamide
    239
    Figure US20170369426A1-20171228-C00258
         		N1-hydroxy-2-(4-(6-hydroxy-5- methylhexa-1,3-diynyl)-N- methylbenzamido)-N3,2- dimethylmalonamide
    240
    Figure US20170369426A1-20171228-C00259
         		N1-hydroxy-2-(4-((3- hydroxycyclobutyl)buta-1,3-diynyl)-N- methylbenzamido)-N3,2- dimethylmalonamide
    241
    Figure US20170369426A1-20171228-C00260
         		N1-hydroxy-2-(4-((3- (hydroxymethyl)cyclobutyl)buta-1,3- diynyl)-N-methylbenzamido)-N3,2- dimethylmalonamide
    242
    Figure US20170369426A1-20171228-C00261
         		N1-hydroxy-2-(4-((3- (hydroxymethyl)cyclopentyl)buta-1,3- diynyl)-N-methylbenzamido)-N3,2- dimethylmalonamide
    243
    Figure US20170369426A1-20171228-C00262
         		N1-hydroxy-2-(4-(6-hydroxy-5- methoxyhexa-1,3-diynyl)-N- methylbenzamido)-N3,2- dimethylmalonamide
    244
    Figure US20170369426A1-20171228-C00263
         		N1-hydroxy-2-(4-(7-hydroxy-6- methoxyhepta-1,3-diynyl)-N- methylbenzamido)-N3,2- dimethylmalonamide
  • Compounds of the present invention can be readily synthesized using the methods described herein, or other methods, that are well known in the art. For example, the synthesis of hydroxamic acids or similar scaffolds having a wide variety of substituents are comprehensively reviewed in Kline, T., et al., “Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC” J. Med Chem. 2002, 45(14), 3112-29; U.S. Pat. No. 5,925,659; Pirrung, M. C., et al., “A Convenient Procedure for the Preparation of Amino Acid Hydroxamates from Esters” J. Org. Chem. 1995, 60, 8084-8085; Nhu, K., et al., “A New and Efficient Solid Phase Synthesis of Hydroxamic Acids” J. Org. Chem. 1997, 62, 7088-7089; International PCT Publication No. WO98/18754; Mellor, S. L., et al., “N-Fmoc-aminoxy-2-chlorotrityl Polystyrene Resin: A Facile Solid-phase Methodology for the Synthesis of Hydroxamic Acids” Tetrahedron Lett. 1997, 38, 3311-3314; Khan, S. I., et al., “A Facile and Convenient Solid-phase Procedure for Synthesizing Nucleoside Hydroxamic Acids” Terahedron. Lett. 1998, 39, 8031-8034; Zhang, Y., et al., “Design, Combinatorial Chemical Synthesis, and in vitro Characterization of Novel Urea Based Gelatinase Inhibitors” Bioorg. Med. Chem. Lett. 1999, 9, 2823-2826; Ito, Y., et al., “Synthetic Reactions by Complex Catalysts. XXXI, A Novel and Versatile Method of Heterocycle Synthesis” J. Am Chem. Soc. 1973, 95, 4447-4448; Ito, Y., et al., “Synthetic Reactions by Complex Catalysts XXXV” Syn. Commun. 1974, 4, 97-103; Witte, H., et al., “Cyclische Imidsaurester aus Nitrilen und Aminoalkoholen” Liebigs Ann. Chem. 1974, 996-1009; Pattenden, G., et al., “Naturally Occurring Linear Fused Thiazoline-Thiazole Containing Metabolites: Total Synthesis of (−) Didehydromirabazole A, a Cytotoxic Alkaloid from Blue-Green Algae” J. Chem. Soc. Perkin Trans 1993, 1, 1629-1636; Boyce, R. J., et al., “Total Synthesis of Thiangazole, A Novel Naturally Occurring HIV-1 Inhibitor from Polyangium sp.” Tetrahedron 1995, 51, 7321-7330; Galeotti, N., et al., “Synthesis of Peptidyl Aldehydes from Thiazolines” Tetrahedron. Lett. 1997, 38, 2459-2462; Charette, A. B., et al., “Mild Method for the Synthesis of Thiazolines from Secondary and Tertiary Amides” J. Org. Chem. 1998, 63, 908-909; Bergeron, R. J., et al., “Effects of C-4 Stereochemistry and C-4′ Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues” J. Med. Chem. 1999, 42, 2432-2440; Raman, P., et al., “Titanium (IV)-mediated Tandem Deprotection-cyclodehydration of Protected Cysteine N-Amides: Biomimetic Synthesis of Thiazoline- and Thiazole-containing Heterocycles” Org. Lett. 2000, 2, 3289-3292; Fernandez, X., et al., “Novel Synthesis of 2-Thioazolines” Tetrahedron Lett. 2000, 41, 3381-3384; and Wipf, P., et al., “C. Thiolysis of Oxazolinenes: A New, Selective Method for the Direct Conversion of Peptide Oxazolines into Thiazolines” Tetrahedron Lett. 1995, 36, 6395-6398, which are incorporated herein by reference.
  • In another aspect, the present invention provides a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
  • In another aspect, the invention provides a method of inhibiting a deacetylase enzyme in a gram-negative bacteria, thereby affecting bacterial growth, comprising administering to a subject in need of such inhibition a compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof.
  • In another aspect, the invention provides a method of inhibiting LpxC, thereby modulating the virulence of a bacterial infection, comprising administering to a subject in need of such inhibition a compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof. In certain embodiments of the method of inhibiting LpxC using a compound of the present invention, the IC50 value of the compound is less than or equal to 10 μM with respect to LpxC. In other embodiments, the IC50 value is less than or equal to 1 μM, is less than or equal to 0.1 μM, is less than or equal to 0.050 μM, is less than or equal to 0.030 μM, is less than or equal to 0.025 μM, or is less than or equal to 0.010 μM.
  • In another aspect, the invention provides a method for treating a subject having a gram-negative bacterial infection comprising administering to the subject in need thereof an antibacterially effective amount of a compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof.
  • In another aspect, the invention provides a method of administering a therapeutically effective amount of a compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof to a subject infected with a fermentative or non-fermentative gram-negative bacteria. Examples of fermentative or non-fermentative gram-negative bacteria include Pseudomonas aeruginosa, Stenotrophomonas maltophila, Burkholderia cepacia, Alcaligenes xylosoxidans, Enterobacteriaceae, Haemophilus, Franciscellaceae (e.g., Franciscella tularensis) and Neisseria species.
  • In another aspect, the invention provides a method of administering an inhibitory amount of a compound described herein to gram-negative bacteria, such as Enterobacteriaceae which is selected from the group consisting of organisms such as Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Providencia, Yersinia (e.g., Yersinia pestis), Morganella, Cedecea, Edwardsiella species and Escherichia coli.
  • In certain embodiments, the subject may be a mammal, and in some embodiments, a human.
  • Bacterial infections susceptible to treatment according to the present invention include primary infections and co-infections caused by a species of bacteria and one or more additional infectious agents such as, for example, bacteria, virus, parasite and fungus.
  • Compounds of the invention can be used for treating conditions caused by the bacterial production of endotoxin and, in particular, by gram-negative bacteria and bacteria that use LpxC in the biosynthesis of lipopolysaccharide (LPS) or endotoxin.
  • Compounds of the invention also are useful in treating conditions that are caused or exacerbated by the bacterial production of lipid A and LPS or endotoxin, such as sepsis, septic shock, systemic inflammation, localized inflammation, chronic obstructive pulmonary disease (COPD) and acute exacerbations of chronic bronchitis (AECB). For these conditions, treatment includes the administration of a compound of the invention, or a combination of compounds of the invention, optionally with a second agent wherein the second agent is a second antibacterial agent or a non-antibacterial agent.
  • For sepsis, septic shock, systemic inflammation, localized inflammation, chronic obstructive pulmonary disease (COPD) and acute exacerbations of chronic bronchitis (AECB), representative non-antibacterial agents include antiendotoxins including endotoxin receptor-binding antibodies, endotoxin-binding antibodies, anti-CD14-binding protein antibodies, antilipopolysaccharide-binding protein antibodies and tyrosine kinase inhibitors.
  • In treatment of serious or chronic respiratory tract infections, compounds of the present invention may also be used with non-antibacterial agents administered via inhalation. Representative non-antibacterial agents used in this treatment include anti-inflammatory steroids, non-steroidal anti-inflammatory agents, bronchiodilators, mucolytics, anti-asthma therapeutics and lung fluid surfactants. In particular, the non-antibacterial agent may be albuterol, salbuterol, budesonide, beclomethasone, dexamethasone, nedocromil, beclomethasone, fluticasone, flunisolide, triamcinolone, ibuprofin, rofecoxib, naproxen, celecoxib, nedocromil, ipratropium, metaproterenol, pirbuterol, salmeterol, formoterol, indacaterol, bronchiodilators, mucolytics, calfactant, beractant, poractant alfa, surfaxin or pulmozyme (also called domase alfa).
  • Compounds of the invention can be used alone or in combination with a second antibacterial agent for the treatment of a serious or chronic respiratory tract infection including serious lung and nosocomial infections such as those caused by Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Serratia marcescens, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Burkholderia cepacia, Alcaligenes xylosoxidans, Flavobacterium meningosepticum, Providencia stuartii and Citrobacter freundi, community lung infections such as those caused by Haemophilus Influenzae, Legionella species, Moraxella catarrhalis, Branhamella catarrhalis, Enterobacter species, Klebsiella species, and Proteus species, infections caused by other bacterial species such as Neisseria species, Shigella species, Salmonella species, Helicobacter pylori, Vibrionaceae and Bordetella species, as well as infections caused by a Brucella species, Francisella tularensis and/or Yersinia Pestis.
  • When used for treating subjects infected with gram-negative bacterial infections, compounds of the present invention can be used to sensitize gram-negative bacteria to the effects of a second agent.
  • The present invention provides novel combinations of compounds including a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, as well as methods for treating subjects infected with gram-negative bacteria. The novel combinations provided herein can be formulated into pharmaceutical formulations and medicaments that are useful in the methods of the invention. The invention also provides for the use of the novel combinations in preparing medicaments and pharmaceutical formulations, for use of the combinations in treating bacterial infections in a subject.
  • In one embodiment, a second antibacterial agent is used in combination with a compound of Formula I, or stereoisomer or pharmaceutically acceptable salt thereof. Examples of suitable second antibactieral agents include, but are not limited to, vancomycin, linezolid, azithromycin, imipenem, teicoplanin, daptomycin, clindamycin, rifampin, cefotaxime, gentamicin, novobiocin or telavancin. In one such embodiment, the antibacterial agent is vancomycin, teicoplanin, rifampin, azithromycin, telavancin or novobiocin. In certain embodiments the second antibacterial agent is vancomycin or rifampin. In some embodiments of the invention, the second antibacterial agent and/or the compound of Formula I, or stereoisomer or pharmaceutically acceptable salt thereof, is administered at a sub-therapeutic dose, wherein a subtherapeutic dose is a dose that would be insufficient to treat bacterial infections, if administered alone.
  • Pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, formulated together with one or more pharmaceutically acceptable carriers or diluents. As used herein, the term “pharmaceutically acceptable carrier” means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials that can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally (as by intravenous, intramuscular or subcutaneous injection), intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, or as an oral or nasal spray, or a liquid aerosol or dry powder formulation for inhalation.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, 1% lidocaine, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
  • The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form.
  • Alternatively, delayed absorption of a parenterally administered drug form may be accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations may also be prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.
  • Compositions for rectal or vaginal administration are preferably suppositories that can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, acetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • The antibacterial compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulations, ear drops, and the like are also contemplated as being within the scope of this invention.
  • The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Compositions of the invention may also be formulated for delivery as a liquid aerosol or inhalable dry powder. Liquid aerosol formulations may be nebulized predominantly into particle sizes that can be delivered to the terminal and respiratory bronchioles where bacteria reside in subjects with bronchial infections, such as chronic bronchitis and pneumonia. Pathogenic bacteria are commonly present throughout airways down to bronchi, bronchioli and lung parenchema, particularly in terminal and respiratory bronchioles. During exacerbation of infection, bacteria can also be present in alveoli. Liquid aerosol and inhalable dry powder formulations are preferably delivered throughout the endobronchial tree to the terminal bronchioles and eventually to the parenchymal tissue.
  • Aerosolized formulations of the invention may be delivered using an aerosol forming device, such as a jet, vibrating porous plate or ultrasonic nebulizer, preferably selected to allow the formation of a aerosol particles having with a mass medium average diameter predominantly between 1 to 5 μm. Further, the formulation preferably has balanced osmolarity ionic strength and chloride concentration, and the smallest aerosolizable volume able to deliver effective dose of the compounds of the invention to the site of the infection. Additionally, the aerosolized formulation preferably does not impair negatively the functionality of the airways and does not cause undesirable side effects.
  • Aerosolization devices suitable for administration of aerosol formulations of the invention include, for example, jet, vibrating porous plate, ultrasonic nebulizers and energized dry powder inhalers, that are able to nebulize the formulation of the invention into aerosol particle size predominantly in the size range from 1-5 μm. Predominantly in this application means that at least 70% but preferably more than 90% of all generated aerosol particles are 1 to 5 μm range. A jet nebulizer works by air pressure to break a liquid solution into aerosol droplets. Vibrating porous plate nebulizers work by using a sonic vacuum produced by a rapidly vibrating porous plate to extrude a solvent droplet through a porous plate. An ultrasonic nebulizer works by a piezoelectric crystal that shears a liquid into small aerosol droplets. A variety of suitable devices are available, including, for example, AeroNeb and AeroDose vibrating porous plate nebulizers (AeroGen, Inc., Sunnyvale, Calif.), Sidestream7 nebulizers (Medic-Aid Ltd., West Sussex, England), Pari LC7 and Pari LC Star7 jet nebulizers (Pari Respiratory Equipment, Inc., Richmond, Va.), and Aerosonic (DeVilbiss Medizinische Produkte (Deutschland) GmbH, Heiden, Germany) and UltraAire7 (Omron Healthcare, Inc., Vernon Hills, Ill.) ultrasonic nebulizers.
  • Compounds of the invention may also be formulated for use as topical powders and sprays that can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • According to the methods of treatment of the present invention, bacterial infections are treated or prevented in a subject such as a human or lower mammal by administering to the subject a therapeutically effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, in such amounts and for such time as is necessary to achieve the desired result. By a “therapeutically effective amount” of a compound of the invention is meant a sufficient amount of the compound to treat bacterial infections, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
  • The total daily dose of the compounds of this invention administered to a human or other mammal in single or in divided doses can be in amounts, for example, from 0.01 to 200 mg/kg body weight or more usually from 0.1 to 50 mg/kg body weight. In certain embodiments, the total daily dose administered to a human or other mammal is from 1.0 to 100 mg/kg body weight or from 5.0 to 25 mg/kg body weight. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. In general, treatment regimens according to the present invention comprise administration to a subject in need of such treatment from about 10 mg to about 15 g of the compound(s) of this invention per day in single or multiple doses, more usually, from 100 mg to 5 g, and even more usually from 250 mg to 1 g per day in single or multiple doses.
  • Methods of formulation are well known in the art and are disclosed, for example, in Remington: The Science and Practice of Pharmacy, Mack Publishing Company, Easton, Pa., 19th Edition (1995). Pharmaceutical compositions for use in the present invention can be in the form of sterile, non-pyrogenic liquid solutions or suspensions, coated capsules, suppositories, lyophilized powders, transdermal patches or other forms known in the art.
  • A “kit” as used in the instant application includes a container for containing the pharmaceutical compositions and may also include divided containers such as a divided bottle or a divided foil packet. The container can be in any conventional shape or form as known in the art that is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a resealable bag (for example, to hold a “refill” of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule. The container employed can depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle that is in turn contained within a box.
  • An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil that is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
  • It maybe desirable to provide a written memory aid, where the written memory aid is of the type containing information and/or instructions for the physician, pharmacist or other health care provider, or subject, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen that the tablets or capsules so specified should be ingested or a card that contains the same type of information. Another example of such a memory aid is a calendar printed on the card e.g., as follows “First Week, Monday, Tuesday,” . . . etc. . . . “Second Week, Monday, Tuesday, . . . ” etc. Other variations of memory aids will be readily apparent. A “daily dose” can be a single tablet or capsule or several tablets or capsules to be taken on a given day. When the kit contains separate compositions, a daily dose of one or more compositions of the kit can consist of one tablet or capsule while a daily dose of another one or more compositions of the kit can consist of several tablets or capsules.
  • Another specific embodiment of a kit is a dispenser designed to dispense the daily doses one at a time in the order of their intended use. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter, that indicates the number of daily doses that has been dispensed. Another example of such a memory-aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal that, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
  • The kits of the present invention may also include, in addition to a compound of the present invention, one or more additional pharmaceutically active compounds. For example, the additional compound second antibacterial. The additional compounds may be administered in the same dosage form as the compound of the present invention or in a different dosage form. Likewise, the additional compounds can be administered at the same time as the compound of the present invention or at different times.
  • Compositions of the present compounds may also be used in combination with other known antibacterial agents of similar spectrum to (1) enhance treatment of severe gram-negative infections covered by the spectrum of this compound or (2) add coverage in severe infections in which multiple organisms are suspected in which another agent of a different spectrum may be required in addition to this compound. Potential agents include members of the aminoglycosides, penicillins, cephalosporins, fluoroquinolones, macrolides, glycopeptides, lipopeptides and oxazolidinones. The treatment can involve administering a composition having both a compound of the present invention and a second antibacterial compound or administration of a compound of the present inventive compounds followed by or preceded by administration of a second antibacterial agent.
  • The foregoing may be better understood by reference to the following examples, that are presented for illustration and not to limit the scope of the inventive concepts.
    • V. EXAMPLES
  • HPLC: Angilent 1200; Mobile Phase: A: water (0.01% TFA) B:ACN (0.01% TFA); Column: ZORBAX SB-C18, 5 um, 4.6*150 mm; Oven Temperature: 50° C. LCMS: Angilent 1200; Mobile Phase: A: water(0.01% TFA) B:ACN(0.01% TFA), Column: SunFire C18 3.5 um, 4.6*50 mm; Oven Temperature: 50° C. GCMS: Agilent instrument (7890A Series gas chromatograph with a Mass Selective Detector 5975C; injector volume: 1 mL; initial column temperature: 40° C.; final column temperature: 250 C; ramp time: 8.4 min; gas flow rate: 1.2 mL/min; column: 5% phenyl methyl silox, Model:Agilent 19091s-433:325C, dimensions: 30.0 m′250 u m′0.25 um) NMR: Bruker AVANCE III 400 MHz, UltraShield-Plus™ Digital NMR
  • A. Compound Synthesis
  • Referring to the examples that follow, compounds of the present invention were characterized by high performance liquid chromatography (HPLC) using a Waters Millennium chromatography system with a 2690 Separation Module (Milford, Mass.) or an Agilent 1200; Mobile Phase: A: water(0.01% TFA) B:ACN(0.01% TFA); Column: ZORBAX SB-C18, 5 um, 4.6*150 mm; Oven Temperature: 50° C. or an Agilent 1100 series chromatography system (Santa Clara, Ca). The analytical columns were Phenomenex Luna C18(2) reversed phase, 10 μm, 100 Å, axia packed, 2.0×50 mm and the preparative columns were Phenomenex Luna C18(2) reversed phase, 10 μm, 100 Å, axia packed, 21.2×250 or 50×250 mm. A gradient elution was used, typically starting with 100% water and progressing to 100% acetonitrile over a varying lengths of time All solvents contained 0.1% acetic acid (AcOH). Compounds were detected by ultraviolet light (UV) absorption at either 220 or 254 nm. In some instances, purity was assessed by thin layer chromatography (TLC) using glass or plastic backed silica gel plates, such as, for example, Baker-Flex Silica Gel 1 B2-F flexible sheets. TLC results were readily detected visually under ultraviolet light, or by employing well known iodine vapor and other various staining techniques
  • Mass spectrometric analysis was performed on one of three LCMS instruments: a Waters System. (Alliance HT HPLC and a Micromass ZQ mass spectrometer; Column: Eclipse XDB-C—18, 2.1×50 mm; solvent system: 5-95% (or 35-95%, or 65-95% or 95-95%) acetonitrile in water with 0.05% TFA; flow rate 0.8 mL/min; molecular weight range 500-1500; cone Voltage 20 V; column temperature 40° C.) or a Hewlett Packard System (Series 1100 HPLC; Column: Eclipse XDB-C18, 2.1×50 mm; solvent system: 1-95% acetonitrile in water with 0.05% TFA; flow rate 0.4 mL/min; molecular weight range 150-850; cone Voltage 50 V; column temperature 30° C.). or an Agilent System (Series 1100 HPLC; Column: Waters Sunfire C18 reversed phase, 2.5 μm, 100 Å, 2.1×50 mm; solvent system: 1-95% acetonitrile in water with 0.1% TFA; flow rate 0.5 mL/min; molecular weight range 150-1500; cone Voltage 70 V; column temperature 35° C.), or an Agilent 1200; Mobile Phase: A:water (0.01% TFA) B:ACN(0.01% TFA), Column: SunFire C18 3.5 um, 4.6*50 mm; Oven Temperature: 50° C. All masses are reported as those of the protonated parent ions.
  • GCMS analysis was performed on a Hewlet Packard instrument (HP6890 Series gas chromatograph with a Mass Selective Detector 5973; injector volume: 1 μL; initial column temperature: 50° C.; final column temperature: 250 C; ramp time: 20 min; gas flow rate: 1 mL/min; column: 5% phenyl methyl siloxane, Model #HP 190915-443, dimensions: 30.0 m×25 m×0.25 m); or Agilent instrument (7890A Series gas chromatograph with a Mass Selective Detector 5975C; injector volume: 1 mL; initial column temperature: 40° C.; final column temperature: 250 C; ramp time: 8.4 min; gas flow rate: 1.2 mL/min; column: 5% phenyl methyl silox, Model:Agilent 19091s-433:325C, dimensions: 30.0 m′250 u m′0.25 um).
  • Nuclear magnetic resonance (NMR) analysis was performed with a Varian 300 MHz NMR (Palo Alto, Calif.). and a Varian Unity Enova 400 MHz NMR spectrometer (Palo Alto, Calif.), or Bruker AVANCE III 400 MHz, UltraShield-Plus™ Digital NMR. The spectral reference was either TMS or the known chemical shift of the solvent. Some compound samples were run at elevated temperatures (e.g. 75° C.) to promote increased sample solubility.
  • Procedure 1 (C-C Coupling Reaction Using CuCl-Cadiot):
  • Hydroxylamine hydrochloride (0.23 mmol, 0.06 eq) and CuCl (0.08, 0.02 eq) were dissolved in 23% aqueous n-butylamine (1 mL) and the resulting solution was cooled to 0° C. A solution of the alkyne (4.3 mmol, 1.1 eq) in 23% aqueous n-butylamine (2 mL) was then added. The bromo-alkyne (3.92 mmol) and hydroxylamine hydrochloride (0.23 mmol, 0.06 eq) were dissolved in 23% aqueous n-butylamine (2 mL) and THF (3 mL), and they were slowly added to the reaction mixture. The reaction was stirred for 1 hr, followed by quenching with EtOAc and water. The organic layer was separated and washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to yield the desired coupled product.
  • Procedure 2 (Boc Deprotection Using TFA):
  • To the Boc-protected compound (3.39 mmol) at 0° C. was added a TFA:DCM solution (9 mL, 2:1) and the reaction was stirred for 1 hr. The reaction was concentrated under reduced pressure to yield a crude residue, which was azeotroped with IPA twice to yield the desired deprotected product.
  • Procedure 3 (Hydroxamate Formation):
  • To a stirring solution of the ester (3.38 mmol) in IPA (4 mL) at 0° C. was slowly added 50% aqueous hydroxylamine (40 eq), and the reaction was stirred overnight. The reaction was quenched with AcOH (0.12 mol, 20 eq) or until the pH was 6. The volatiles were removed under reduced pressure, and the resulting solution was purified by RP HPLC.
  • Procedure 4A (Formation of Imine in Reductive Amination to NHMe):
  • To a stirring solution of the amine (2.37 g, 7.20 mmol) in DMF (14.39 mL) was added DIPEA (1.88 mL, 10.79 mmol) followed by formaldehyde (37% in water) (1.07 mL, 14.39 mmol) and the reaction was stirred for 2 hr. The excess aldehyde was quenched with n-butylamine (30% in water) (2.63 g, 10.79 mmol) and stirred for 1 hr. The reaction mixture was diluted with water, and lyophilized to yield the desired imine.
  • Procedure 4B (Reduction to Amine in Reductive Amination to NHMe):
  • To a stirring solution of the imine (3.96 g, 11.60 mmol) in THF (23.17 mL) and MeOH (2.439 mL) was added acetic acid (1.33 mL, 23.20 mmol) followed by sodium cyanoborohydride (10.94 g, 174 mmol) and the reaction was stirred for 1 hr. The reaction mixture was diluted with water (7 mL) and concentrated under reduced pressure to yield the amine.
    • 4-(bromoethynyl) benzoic acid (INT-1)
  • Figure US20170369426A1-20171228-C00264
  • Ethynyltrimethylsilane (82.4 g, 0.84 mol) was added dropwise over 10 min under a nitrogen atmosphere to a solution of methyl 4-bromobenzoate (150 g, 0.7 mol), PdCl2 (PPh3)2(15 g, 0.021 mol) and CuI (13 g, 0.07 mol) in TEA (1.5 L) and the reaction was stirred at 90° C. for 30 minutes. Solids were collected by filtration and washed with EtOAc (5×500 mL). The filtrate was concentrated under reduced pressure to give a residue, which was distilled under reduced pressure to yield methyl 4-((trimethylsilyl) ethynyl) benzoate (INT-1.2) as an off-white solid (156 g, 96%).
  • To a solution of methyl 4-((trimethylsilyl) ethynyl)benzoate (156 g, 0.67 mol) in methanol (800 mL) was added dropwise KOH/methanol (18 g/250 mL) keeping the temperature below 10° C. The reaction mixture was allowed to warm to room temperature for 5 min and was then neutralized with 2M HCl. Methyl 4-ethynylbenzoate (INT-1.3) was collected by filtration as a white solid (97 g, 90%). MS: m/z calcd for C10H8O2160.0, found [M+H]+ 161.
  • Figure US20170369426A1-20171228-C00265
  • To a solution of methyl 4-ethynylbenzoate (50 g, 0.31 mol) in acetone (750 mL) was added AgNO3 (5 g, 29.7 mmol) and the reaction mixture was stirred for 1 hr. NBS (61.2 g, 0.34 mol) was added and the reaction mixture was stirred at room temperature for 20 hr, filtered and concentrated under reduced pressure. The residue was diluted in EA, and washed with iced 20% H2SO4. The organic layer was washed with water and brine, dried (Na2SO4), filtered, concentrated under reduced pressure to give a residue, which was recrystallized from MeOH (1 mL/4 g) to yield methyl 4-(bromoethynyl) benzoate (INT-1.4) as an off-yellow solid (67 g, 90%). 1H NMR (400 MHz, CDCl3) δ 7.98 (d, J=8.8 Hz, 2H), 7.51 (d, J=8.8 Hz, 2H), 3.92 (s, 3H).
  • To a solution of methyl 4-(bromoethynyl) benzoate (67 g, 280 mmol) in CH3OH/THF/H2O=5/5/1 (1100 mL) was added NaOH (44.84 g) and the reaction mixture was stirred at 25° C. for 3 hr. The volatiles were removed under reduced pressure and the resulting solution was neutralized with 1 N HCl to pH 3-5. Solids were collected by filtration, washed with water and dried at 50° C. for 5 hr to yield 4-(bromoethynyl) benzoic acid (INT-1) (61 g, 96%).
    • 1. N-hydroxy-2-(4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)phenyl)-1, 6-naphthyridine-4-carboxamide (1)
  • Figure US20170369426A1-20171228-C00266
  • To a stirring solution of 4-amino-3-bromopyridine (1.1, 173 mg, 1 mmol) and Et3N (132 mg, 1.3 mmol) in DCM (5 mL) was added dropwise pivaloyl chloride (133 mg, 1.1 mmol), and the reaction was stirred at room temperature for 3 hr. The mixture was washed with water (2×), NaHCO3, brine, dried and concentrated under reduced pressure to give the product 1.2 as a solid. MS: m/z calcd for C10H13BrN2O 256.02/258.02, found [M+H]+ 257/259.
  • Figure US20170369426A1-20171228-C00267
  • A mixture of compound 1.2 (5 g, 19.4 mmol) and 10% Pd/C (500 mg) in MeOH (70 mL) was stirred under H2 (1 atm) at room temperature overnight. The Pd/C was removed by filtration and the solvent was concentrated under reduced pressure to yield a crude, which was dissolved in EtOAc. The organic layer was washed with NaHCO3, brine, dried and concentrated under reduced pressure to give the product 1.3 as a solid. MS: m/z calcd for C10H14N2O 178.11, found [M+H]+ 179.
  • Figure US20170369426A1-20171228-C00268
  • To a solution of compound 1.3 (5.34 g, 30 mmol) in THF (200 mL) at −78° C. was added dropwise n-BuLi (47 mL, 75 mmol) and the reaction was stirred for 3 hr at −10° C. The reaction was cooled to −78° C. and a solution of diethyl oxalate (22 g, 150 mmol) in THF (20 mL) was added dropwise and the mixture was stirred overnight at room temperature. NH4Cl was added, and the reaction was extracted with EtOAc, washed with brine, dried, concentrated under reduced pressure and purified by flash chromatography (silica gel/EtOAc/PE 1:10-1:8) to give the product 1.4 as a solid. MS: m/z calcd for C14H18N2O4 278.13, found [M+H]+ 279.
  • Figure US20170369426A1-20171228-C00269
  • Compound 1.7 was synthesized according to the procedure described in International PCT Patent Application Publication No. WO2012/154204.
  • Figure US20170369426A1-20171228-C00270
    • 1-(4-((trimethylsilyl)ethynyl)phenyl)ethanone (1.9)
  • Reagent MW Eq. mmol g, mL
    Compound 1.8 198 1.0 101 20 g
    ethynyl(trimethyl)silane 98 1.4 141 13.8 g
    Pd(PPh3)2Cl2 701 0.05 5.1 3.6 g
    Cul 190 0.1 10 1.9
    TEA 300 mL
  • To a stirring solution of compound 1.8 (20 g, 101 mmol), Pd(PPh3)2Cl2 3.6 g, 141 mmol), CuI (1.9 g, 10 mmol) in TEA (300 mL) under argon was added ethynyl(trimethyl)silane (13.8 g, 141 mmol) at 90° C. and the reaction mixture was stirred at 90° C. for 4 hr. The solids were removed by filtration, and rinsed with ethyl acetate (3×80 mL). The filtrate was concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/ethyl acetate in petroleum ether 5%-10% v/v) to give compound 1.9 as a yellow oil (19 g, 90%). 1H NMR (400 MHz, DMSO-d6) δ 7.92 (d, J=8, 2H), 7.56 (d, J=8, 2H), 2.56 (s, 3H), 0.23 (s, 9H).
    • 1-(4-ethynylphenyl)ethanone (1.10)
  • Reagent MW Eq. mmol g, mL
    Compound 1.9 216 1.0 88 19 g
    KOH 56 0.5 44 2.46 g
    MeOH 200 mL
  • To a stirring solution of compound 1.9 (19 g, 88 mmol) in MeOH (200 mL) was added a solution of KOH (2.46 g, 44 mmol) in MeOH (20 mL) at 10° C. and the mixture was stirred at room temperature for 1 hr. AcOH was added until the pH was 7, and the reaction mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (200 mL), washed with 5% aqueous NaHCO3 (100 mL), brine (100 mL), dried, and concentrated under reduced pressure to give compound 1.10 as a white solid (12 g, 95%). 1H NMR (400 MHz, DMSO-d6) δ 7.95 (d, J=8, 2H), 7.62 (d, J=8, 2H), 4.49 (s, 1H), 2.59 (s, 3H).
    • 1-(4-(bromoethynyl)phenyl)ethanone 1.11
  • Reagent MW Eq. Mmol g, mL
    Compound 1.11 144 1.0 83.3 12 g
    NBS 177 1.2 99.96 17.7 g
    AgNO3 169 0.095 7.9 1.34 g
    Acetone 200 mL
  • To a stirring solution of compound 1.10 (12 g, 83.3 mmol) in acetone (200 mL) was added AgNO3 (1.34 g, 7.9 mmol) and the the reaction was stirred for 30 min. NBS (17.7 g, 99.96 mmol) was then added and the reaction mixture was stirred at 20° C. for 14 hr. Solids were removed by filtration and the filtrate was concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/ethyl acetate in petroleum ether 5%-10% v/v) to give compound 1.11 as a white solid (14 g, 76%). 1H NMR (400 MHz, DMSO-d6) δ 7.95 (d, J=8, 2H), 7.62 (d, J=8, 2H), 2.58 (s, 3H).
    • 1-(4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)phenyl)ethanone (1.12)
  • Reagent MW Eq. mmol g, mL
    Compound 1.11 198 1.0 4.5 1.0 g
    Compound 1.7 96 1.5 6.75 648 mg
    Pd(PPh3)2Cl2 701 0.05 0.225 158 mg
    Cul 190 0.1 0.45 90 mg
    TEA 101 2 9 1.16 g
    THF 30 mL
  • To a stirring solution of compound 1.11 (1.0 g, 4.5 mmol), compound 1.7 (648 mg, 6.75 mmol), Pd(PPh3)2Cl2 (158 mg, 0.22 mmol), and CuI (90 mg, 0.45 mmol) in THF (30 mL) under argon was added TEA (1.16 g, 9 mmol) and the mixture was stirred at 20° C. for 14 hr. Solids were removed by filtration and rinsed with ethyl acetate (3×80 mL), the filtrate was concentrated under reduced pressure to yield a crude, which was purified by flash chromatography (silica gel/ethyl acetate in petroleum ether 15%-50% v/v) to give compound 1.12 as a yellow solid (450 mg, 42%). MS: m/z calcd for C16H14O2 238.1, found [M+H]+ 239. 1H NMR (400 MHz, CDCl3) δ 7.89 (d, J=8.4, 2H), 7.53 (d, J=8.4, 2H), 3.61 (dd, J=6, 11.6, 1H), 3.51 (dd, J=6.8, 11.6, 1H), 2.59 (s, 3H), 1.57-1.62 (m, 1H), 1.49 (brs, 1H), 1.37-1.41 (m, 1H), 1.06-1.10 (m, 1H), 0.88-0.93 (m, 1H).
  • Figure US20170369426A1-20171228-C00271
  • To a stirring solution of compound 1.4 (139 mg, 0.5 mmol) in EtOH (10 mL) was added KOH (112 mg, 2.0 mmol, 4 M), and the reaction was heated at 100° C. for 3 hr. Racemic compound 1.12 (178.5 mg, 0.75 mmol) was added and the mixture was stirred overnight at 100° C. The solvent was concentrated under reduced pressure. Water was added, and the reaction was washed with Et2O. The reaction mixture was adjusted to pH 1-2 with acetic acid, and the resulting solids were collected by filtration and dried to yield the desired product 1.13. MS: m/z calcd for C23H16N2O3 368.12, found [M+H]+ 369.
  • Figure US20170369426A1-20171228-C00272
  • To a stirring solution of compound 1.13 (184 mg, 0.5 mmol) in DMF (10 mL) was added K2CO3 (138 mg, 1.0 mmol), followed by iodomethane (74.55 mg, 0.52 mmol) and the reaction was stirred overnight at room temperature. The reaction was quenched with water, extracted with EtOAc, washed with brine, dried, concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/PE:EtOAc 1.5:1-1:1.5) to yield a solid, which was recrystallized from EA/PE (1:5) to give the desired product 1.14. MS: m/z calcd for C24H18N2O3 382.13, found [M+H]+ 383.
  • Figure US20170369426A1-20171228-C00273
  • Compound 1.14 (500 mg) was converted to N-hydroxy-2-(4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)phenyl)-1,6-naphthyridine-4-carboxamide (1, 339 mg, 68%) using Procedure 3: MS: m/z calcd for C23H17N3O3 383.13, found [M+H]+ 384.
    • 2. N-hydroxy-4-(4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)phenyl)picolinamide (2)
  • Figure US20170369426A1-20171228-C00274
  • To a stirring solution of compound 2.1 (27.8 g, 0.15 mol), compound 2.2 (45.7 g, 0.18 mol) and PdCl2(PPh3)2(5.26 g, 7.5 mmol) in 1,4-dioxane (500 mL), was added KOAc (22.0 g, 0.225 mol) under an argon atmosphere and the mixture was stirred at 80° C. for 15 hr. The solvent was removed under reduced pressure, and the residue was diluted with PE (500 mL). Solids were removed by filtration, and the filtrate was concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/PE:EA 10:1) to give 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (2.3, 32.5 g, 95%) as a white solid.
  • Figure US20170369426A1-20171228-C00275
  • To a stirring solution of compound 2.3 (32.4 g, 0.14 mol), compound 2.4 (32.2 g, 0.17 mol) and Pd(PPh3)4(8.08 g, 7 mmol) in 1,4-dioxane/methanol (800 mL, 1:1) was added Na2CO3 (22.3 g, 0.21 mol) under an argon atmosphere and the mixture was stirred at 80° C. for 15 hr. The solvent was removed under reduced pressure and the resulting residue was diluted with water (500 mL) and extracted with EtOAc (3×500 mL). The combined organic layers were dried and concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/PE:EA 2:1) to give ethyl 4-(4-formylphenyl)picolinate (2.5, 14.2 g, 40%) as a yellow solid.
  • Figure US20170369426A1-20171228-C00276
  • To a stirring solution of compound 2.5 (12.7 g, 50 mmol) in CH3OH (300 mL) was added the Bestmann reagent (14.4 g, 75 mmol) followed by K2CO3 (20.8 g, 150 mmol) and the reaction was stirred for 5 hr. The reaction mixture was diluted with water (500 mL) and extracted with Et2O (3×300 mL). The combined organic layers were dried and concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/PE:Et2O 10:1-5:1) to give methyl 4-(4-ethynylphenyl)picolinate (2.6, 4.0 g, 33.9%) as a white solid.
  • Figure US20170369426A1-20171228-C00277
  • To a stirring solution of racemic compound 2.7 (4.8 g, 50 mmol) and AgNO3 (0.85 g, 5 mmol) in acetone (200 mL) was added NBS (10.7 g, 60 mmol) under an argon atmosphere and the mixture was stirred at room temperature for 15 hr. The mixture was filtered and the residue was taken up with acetone, the combined organic layers were concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/PE:EA 5:1) to give (2-trans-(bromoethynyl)cyclopropyl)methanol (2.8, 5.2 g, 60%) as a colorless oil.
  • Figure US20170369426A1-20171228-C00278
  • To a stirring solution of compound 2.6 (1.77 g, 7.5 mmol), Pd(PPh3)2Cl2 (262 mg, 0.37 mmol), CuI (143 mg, 0.75 mmol), and DIPEA (2.9 g, 22.5 mmol) in THF (50 mL) was added compound 2.8 (1.84 g, 10.5 mmol) under an argon atmosphere, and the mixture was stirred at room temperature for 5 hr. The solvent was removed under reduced pressure, and the resulting residue was diluted with water (100 mL) and extracted with EtOAc (3×150 mL). The combined organic layers were dried and concentrated under reduced pressure to give a red oil, which was purified by flash chromatography (silica gel/PE:EA 5:1˜3:1) to yield methyl 4-(4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)phenyl)picolinate (2.9, 570 mg, 23%): MS: m/z calcd for C21H17NO3 331.12, found [M+H]+ 332; 1H-NMR (DMSO-d6, 400 MHz) δ 8.77 (d, J=5.6 Hz, 1H), 8.30 (s, 1H), 7.99 (d, J=5.6 Hz, 1H), 7.90 (d, J=8.4 Hz, 2H), 7.67 (d, J=8.4 Hz, 2H), 4.72 (t, J=5.6 Hz, 1H), 3.91 (s, 3H), 3.44 (m, 1H), 3.24 (m, 1H), 1.45 (m, 2H), 0.88 (m, 2H).
  • Figure US20170369426A1-20171228-C00279
  • Methyl 4-(4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)phenyl)picolinate (2.9, 500 mg) was treated according to Procedure 3 to give N-hydroxy-4-(4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)phenyl)picolinamide (2, 157 mg, 31%). MS: m/z calcd for C20H16N2O3 332.12, found [M+H]+ 333.1.
    • 3. N—((R)-1-(hydroxyamino)-3-methyl-3-(methylthio)-1-oxobutan-2-yl)-4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamide (3)
  • Figure US20170369426A1-20171228-C00280
  • To a stirring suspension of (R)-2-amino-3-mercapto-3-methylbutanoic acid (3.1, 9 g, 60.3 mmol) in DMF (20 mL) was added BOC-anhydride (14.0 mL, 60.3 mmol) followed by TEA (8.41 mL, 63.3 mmol) and the reaction mixture was stirred for 18 hr. Excess solvent was removed under reduced pressure. The crude product was treated with methyl iodide (18.83 g, 133 mmol) in DMF (20 mL) and Cs2CO3 (43.2 g, 133 mmol) at room temperature for 18 hr. Water (100 mL) was added and the product was extracted with ethyl acetate (2×200 mL), dried (Na2SO4) and concentrated under reduced pressure to give compound 3.2 (12.62 g) as a white solid. Subsequent BOC deprotection was achieved by treatment with TFA (20 mL) in CH2Cl2 (20 mL) for 5 hr. The solvent was removed under reduced pressure to give the desired product 3.3 (8.2 g).
  • Figure US20170369426A1-20171228-C00281
  • A stirring solution of racemic ((trans)-2-ethynylcyclopropyl)methanol (1.7, 11 g, 106 mmol), copper(I) chloride (0.20 g, 2.03 mmol), and hydroxylamine hydrochloride (0.42 g, 6.08 mmol) in 30% aqueous butylamine (156 mL) was poured into a 1 L jacketed reactor and cooled to 0° C. A solution of 4-(bromoethynyl)benzoic acid (INT-1, 22.81 g, 101 mmol) and hydroxylamine hydrochloride (0.42 g, 6.08 mmol) in 30% aqueous butylamine (111 mL) was then added dropwise and the reaction was stirred for 2 hr. The reaction mixture was washed with MTBE (2×230 mL) and the aqueous layer was diluted with methyl THF (460 mL). The solution was cooled to 00° C. and acidified by dropwise addition of 6M HCl (100 ml) to pH 1. The reaction mixture was filtered through Celite, and washed with methyl-THF (230 ml). The two layers were partitioned and the aqueous layer was back-extracted with methyl-THF (230 mL). The organic layers were washed with 2M HCl (2×230 mL), water (230 ml), and brine (230 ml), dried over Na2SO4 and filtered. The organic layer was concentrated under reduced pressure until the solution turned cloudy, then heptane (230 mL) was added. The resulting solution was concentrated under reduced pressure to 5 volumes and then additional heptane (230 mL) was added. The resulting solution was concentrated to 5 volumes to give a slurry. The solids were collected by filtration, washed with heptane (50 mL), and dried under reduced pressure to yield 4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzoic acid (3.4, 3.96 g). MS: m/z calcd for C15H12O3 240.08, found [M−H]+239.1. 1H NMR (DMSO-d6, 400 MHz) δ 13.18 (s, 1H), 7.85 (d, 2H), 7.61 (d, 2H), 4.72 (t, 1H), 3.39-3.52 (m, 1H), 3.21-3.32 (m, 1H), 1.41-1.51 (m, 2H), 0.81-0.99 (m, 2H).
  • Figure US20170369426A1-20171228-C00282
  • To a stirring solution of triethylamine (1.06 g, 10.52 mmol), and (R)-methyl 2-amino-3-methyl-3-(methylthio)butanoate (3.3, 1.86 g, 10.52 mmol) was added a solution of racemic 4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzoic acid (3.4, 2.5 g, 10.52 mmol) in DMF (40 mL), followed by 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (4 g, 10.52 mmol) and the reaction was stirred for 2 hr. Water (100 mL) was added and the mixture was extracted with ethyl acetate (2×100 mL), dried (Na2SO4) and concentrated under reduced pressure to yield a crude, which was purified by flash chromatography (silica gel/ethyl acetate 10-40% in hexanes) to yield the corresponding ester 3.5 (2.6 g), which was converted to N—((R)-1-(hydroxyamino)-3-methyl-3-(methylthio)-1-oxobutan-2-yl)-4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzamide (3) using Procedure 3. MS: m/z calcd for C21H24N2O4S 400.15, found [M+H]+ 401.
    • 4. N-((2R)-1-(hydroxyamino)-3-methyl-3-(methylsulfinyl)-1-oxobutan-2-yl)-4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamide (4)
  • Figure US20170369426A1-20171228-C00283
  • To a stirring solution of N—((R)-1-(hydroxyamino)-3-methyl-3-(methylthio)-1-oxobutan-2-yl)-4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzamide (3, 0.2 g, 0.50 mmol) in acetonitrile/water (20 mL) was added 30% aqueous hydrogen peroxide (0.015 mL, 0.50 mmol) and the reaction mixture was stirred at room temperature for 18 hr. The reaction mixture was lyophylized to afford N-((2R)-1-(hydroxyamino)-3-methyl-3-(methylsulfinyl)-1-oxobutan-2-yl)-4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzamide (4, 200 mg, 449 mmol, 90%). MS: m/z calcd for C21H24N2O5S 416.14, found [M+H]+ 417.
    • 5. N—((R)-1-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-1-oxobutan-2-yl)-4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamide (5)
  • Figure US20170369426A1-20171228-C00284
  • N—((R)-1-(hydroxyamino)-3-methyl-3-(methylthio)-1-oxobutan-2-yl)-4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzamide (3, 120 mg, 0.3 mmol) in 22% acetonitrile-water (100 mL) was treated with 30% peracetic acid (1 mL) overnight at room temperature. The reaction was lyophilized to afford N—((R)-1-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-1-oxobutan-2-yl)-4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzamide (5, 130 mg). MS: m/z calcd for C21H24N2O6S 432.14, found [M+H]+ 433.
    • 6. N—((S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)-2-naphthamide (6)
  • Figure US20170369426A1-20171228-C00285
  • To a stirring solution of 6-bromo-2-naphthoic acid (6.1, 1.0 g, 4.0 mmol), racemic ((trans)-2-ethynylcyclopropyl)methanol (1.7, 0.5 g, 5.2 mmol), copper(I) iodide (30 mg, 0.16 mmol) and palladium(II) bis(triphenylphosphine) dichloride (56 mg, 0.08 mmol) in tetrahydrofuran (7.5 mL) under a nitrogen atmosphere was added triethylamine (2.5 mL) and the reaction was stirred for 1 week. The reaction was partitioned between 2N aqueous sodium hydroxide and ethyl acetate. The aqueous layer was acidified with conc HCl and extracted with ethyl acetate. The organic layer was washed with water, saturated sodium chloride and dried over magnesium sulfate, filtered and concentrated under reduced pressure to give 6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)-2-naphthoic acid (6.2, 1.0 g, 94%).
  • Figure US20170369426A1-20171228-C00286
  • To a stirring suspension of (S)-methyl-2-amino-3-((tert-butoxycarbonyl)amino)-3-methylbutanoate oxalate (6.3, 1.6 g, 4.9 mmol) and 6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)-2-naphthoic acid (6.2, 1.0 g, 3.8 mmol) in ACN (10 mL) at 00° C. was added triethylamine (2.1 mL, 15 mmol), followed by the portionwise addition of a solution of HATU (3.0 g, 7.9 mmol) in ACN (10 mL) and the reaction mixture was stirred at 00° C. for 75 min. The reaction was concentrated under reduced pressure to yield a residue, which was partitioned between MTBE and water. The organic layer was washed with 1M citric acid, water, saturated sodium bicarbonate (2×), saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give (S)-methyl 3-((tert-butoxycarbonyl)amino)-2-(6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)-2-naphthamido)-3-methylbutanoate (6.4), which was carried through to the next step without further purification.
  • Figure US20170369426A1-20171228-C00287
  • To a stirring solution of (S)-methyl 3-((tert-butoxycarbonyl)amino)-2-(6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)-2-naphthamido)-3-methylbutanoate (6.4) in methanol (10 mL) was added 4N HCl in dioxane (10 mL) and the reaction mixture was stirred at rt for 2 hr, then at 4° C. overnight. The mixture was concentrated under reduced pressure to give a residue, which was partitioned between water and MTBE. The aqueous layer was basified with saturated sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give (S)-methyl 3-amino-2-(6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)-2-naphthamido)-3-methylbutanoate (6.5, 1.2 g, 3.0 mmol, 79%).
  • Figure US20170369426A1-20171228-C00288
  • Compound 6.5 (1.2 g) was treated according to Procedure 3 to yield the desired compound N—((S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)-2-naphthamide (6, 400 mg, 1.01 mmol, 33.3% yield). MS: m/z calcd for C22H25N3O4 395.18, found [M+H]+ 396.2.
    • 7. N—((S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)benzo[b]thiophene-2-carboxamide (7)
  • Figure US20170369426A1-20171228-C00289
  • To a stirring solution of 6-bromobenzo[b]thiophene-2-carboxylic acid (7.1, 1.0 g, 3.9 mmol) in DMF (7.5 mL) under a nitrogen atmosphere were added racemic ((trans)-2-ethynylcyclopropyl)methanol (1.7, 935 mg, 9.7 mmol), copper(I) iodide (30 mg, 0.16 mmol) and palladium(II) bis(triphenylphosphine) dichloride (56 mg, 0.08 mmol), followed by triethylamine (2.5 mL) and the reaction was stirred at room temperature for 1 hr, and then at 40° C. for 20 hr. The reaction mixture was partitioned between 2N aqueous sodium hydroxide and ethyl acetate. The aqueous layer was acidified with conc HCl and extracted with ethyl acetate. The resulting organic layer was washed with water, saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give 6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)benzo[b]thiophene-2-carboxylic acid (7.2, 900 mg, 3.3 mmol, 85%).
  • Figure US20170369426A1-20171228-C00290
  • To a stirring solution of (S)-methyl 2-amino-3-((tert-butoxycarbonyl)amino)-3-methylbutanoate oxalate 6.3 (1.4 g, 4.3 mmol), 6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)benzo[b]thiophene-2-carboxylic acid (7.2, 900 mg, 3.3 mmol) in ACN (10 mL) at 0° C. was added triethylamine (1.8 mL, 13 mmol), followed by the portionwise addition of a suspension of HATU (2.6 g, 6.9 mmol) in ACN (10 mL), and the reaction mixture was stirred at 00° C. for 105 min. The reaction mixture was concentrated under reduced pressure, and the residue was partitioned between MTBE and water. The organic layer was washed with 1M citric acid, water, saturated sodium bicarbonate (2×), saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give (S)-methyl 3-((tert-butoxycarbonyl)amino)-2-(6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)benzo [b]thiophene-2-carboxamido)-3-methylbutanoate (7.3), which was carried through to the next step without further purification.
  • Figure US20170369426A1-20171228-C00291
  • To a stirring solution of (S)-methyl 3-((tert-butoxycarbonyl)amino)-2-(6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)benzo[b]thiophene-2-carboxamido)-3-methylbutanoate (7.3) in methanol (10 mL) was added 4N HCl in dioxane (10 mL) and the reaction was stirred at room temperature for 2 hr, then at 4° C. overnight. The reaction mixture was concentrated under reduced pressure to yield a residue, which was partitioned between water and MTBE. The aqueous layer was basified with saturated sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give (S)-methyl 3-amino-2-(6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)benzo[b]thiophene-2-carboxamido)-3-methylbutanoate (7.4, 880 mg, 2.2 mmol, 67%).
  • Figure US20170369426A1-20171228-C00292
  • Compound 7.4 (0.88 g) was treated according to Procedure 3 to yield the desired compound N—((S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-6-(((trans)-2-(hydroxymethyl)cyclopropyl)ethynyl)benzo[b]thiophene-2-carboxamide (7, 16.3 mg, 0.041 mmol, 1.85% yield). MS: m/z calcd for C20H23N3O4S 401.14, found [M+H]+ 402.2.
    • 8. N1-hydroxy-2-(4-(((1R,2R)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamido)-N3-methylmalonamide (8)
  • Figure US20170369426A1-20171228-C00293
  • To a stirring solution of diethyl 2-((tert-butoxycarbonyl)amino)malonate (8.1, 0.93 mL, 3.63 mmol) in methanol (10 mL) was added 40% methanamine in water (0.32 mL, 3.63 mmol) and the reaction was stirred at room temperature for 27 days. The reaction was concentrated under reduced pressure to give an oil, which was purified by flash chromatography (silica gel/10% MeOH/DCM) to provide compound 8.2 (592 mg, 66.2% yield). MS: m/z calcd for C10H18N2O5 246.12, found [M+Na]+ 269.1.
  • Figure US20170369426A1-20171228-C00294
  • Compound 8.2 (0.59 g, 2.40 mmol) was dissolved in DCM (3 mL) and TFA (3 mL) and the reaction was stirred for 30 min. The reaction mixture was concentrated under reduced pressure to give compound 8.3 (0.88 g), which was carried through to the next step without further purification. MS: m/z calcd for C5H10N2O3 146.07, found [M+H]+ 147.1.
  • Figure US20170369426A1-20171228-C00295
    Figure US20170369426A1-20171228-C00296
  • The synthesis of compound 8.14 was carried out as described in International PCT Patent Application Publication No. WO2012/154204.
  • Figure US20170369426A1-20171228-C00297
  • To a stirring solution of compound 8.3 (375 mg, 1.44 mmol) in ACN (3 mL) was added compound 8.14 (315 mg, 1.31 mmol), followed by DIPEA (1.01 mL, 5.77 mmol) and the reaction mixture was cooled to 00° C. HATU (548 mg, 1.44 mmol) was added and the reaction was allowed to warm to room temperature. After 1 hr solids were collected by filtration, and washed with ACN to yield compound 8.15 (200 mg, 41.4% yield). MS: m/z calcd for C20H20N2O5 368.14, found [M+H]+ 369.1.
  • Figure US20170369426A1-20171228-C00298
  • To a stirring solution of compound 8.15 (200 mg, 0.54 mmol) in THF (1.0 mL) and methanol (1 mL) was added dropwise over 1 min a solution of 50% hydroxamic acid in water (1 mL) and the reaction was stirred at room temperature for 3 hr. The reaction mixture was concentrated under reduced pressure to give a crude, which was purified by RP HPLC (0.1% AcOH in water and ACN) to give N1-hydroxy-2-(4-(((1R,2R)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamido)-N3-methylmalonamide (8, 47.7 mg, 23.8% yield). MS: m/z calcd for C19H19N3O5 369.13, found [M+H]+ 370.1. 1H NMR (DMSO-d6, 400 MHz) δ 10.84 (br, 1H), 9.06 (s, 1H), 8.57 (d, 1H), 8.02 (d, 1H), 7.89 (d, 2H), 7.60 (d, 2H), 4.99 (d, 1H), 4.70 (t, 1H), 3.43-3.37 (m, 1H), 3.29-3.22 (m, 1H), 2.60 (d, 3H), 1.46-1.41 (m, 2H), 0.94-0.86 (m, 2H).
    • 9. N-hydroxy-4-(4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)phenyl)-2-methyl-2-(methylsulfonyl)butanamide (9)
  • Figure US20170369426A1-20171228-C00299
  • A solution of 2-(4-bromophenyl)ethanol (20.0 g, 100 mol) in CH2Cl2 (10 mL) was added dropwise to a solution of imidazole (22.4 mg, 0.33 mmol), PPh3 (33.3 g, 127 mmol), and I2 (32.5 g, 130 mmol) in CH2Cl2 (50 mL) at 00° C., and the reaction was warmed to room temperature and stirred overnight. The reaction mixture was washed with saturated aqueous sodium thiosulfate (2×50 mL), brine, dried over Na2SO4, filtered and concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/PE) to yield 1-bromo-4-(2-iodoethyl)benzene (9.2, 22.7 g, 73%) as a white solid. 1H NMR (400 MHz, CDCl3) 53.13 (t, J=7.6 Hz, 2H), 3.32 (t, J=7.6 Hz, 2H), 7.07 (d, J=8.0 Hz, 2H), 7.44 (d, J=8.2 Hz, 2H).
    • Methyl 4-(4-bromophenyl)-2-methyl-2-(methylsulfonyl)butanoate
  • Figure US20170369426A1-20171228-C00300
  • Compound 9.3 was synthesized according to the procedure described in WO 2011045703.
  • Figure US20170369426A1-20171228-C00301
  • To a stirring suspension of methyl 4-(4-bromophenyl)-2-methyl-2-(methylsulfonyl)butanoate (9.3, 6.36 g, 18.23 mmol), bis(triphenylphosphine)palladium(II) chloride (1.28 mg, 1.82 mmol) and copper(I) iodide (347 mg, 1.82 mmol) in triethylamine (30 mL) was added ethynyltrimethylsilane (0.92 mL, 6.49 mmol) and the reaction mixture was heated to 80° C. briefly, and then allowed to stir at room temperature for 18 hr. Volatiles were removed under reduced pressure and the resulting residue was purified by flash chromatography (silica gel/15-50% EtOAc/hexanes) to yield methyl 2-methyl-2-(methylsulfonyl)-4-(4-((trimethylsilyl)ethynyl)phenyl)butanoate (9.4, 4.0 g, 59.9% yield). MS: m/z calcd for C18H26O4SSi 366.13, found [M+H]+ 367.2.
  • Figure US20170369426A1-20171228-C00302
  • To a stirring solution of methyl 2-methyl-2-(methylsulfonyl)-4-(4-((trimethylsilyl)ethynyl)phenyl)butanoate (9.4, 4.4 g, 12.0 mmol) in methanol (80 mL) was added K2CO3 (100 mg, 0.720 mmol) and the reaction was stirred at room temperature for 3 hr. The reaction mixture was filtered through celite, concentrated under reduced pressure to give a residue, which was dissolved in DCM, filtered and concentrated under reduced pressure to yield methyl 4-(4-ethynylphenyl)-2-methyl-2-(methylsulfonyl)butanoate (9.5, 2.49 g, 70.5%). MS: m/z calcd for C15H18O4S 294.09, found [M+H]+ 295.2.
  • Figure US20170369426A1-20171228-C00303
  • To a stirring solution of methyl 4-(4-ethynylphenyl)-2-methyl-2-(methylsulfonyl)butanoate (9.5, 2.49 g, 8.46 mmol) and silver nitrate (144 mg, 0.85 mmol) in acetone (24 mL) was added NBS (2.5 g, 14.33 mmol) and the reaction was stirred at room temperature for 1.5 hr. Solvent was removed under reduced pressure to give a residue, which was purified by flash chromatography (silica gel/30-50% EtOAc/hexanes) to yield methyl 4-(4-(bromoethynyl)phenyl)-2-methyl-2-(methylsulfonyl)butanoate (9.6, 150 mg, 0.40 mmol, 4.75%). MS: m/z calcd for C15H17BrO4S 372.0/374.0, found [M+H]+ 373.0/375.0.
  • Figure US20170369426A1-20171228-C00304
  • To a stirring solution of racemic ((trans)-2-ethynylcyclopropyl)methanol (1.7) in n-butylamine (750 μL, 30% in 1:1 water/THF) at −10° C. was added a solution of copper chloride (4 mg) in n-butylamine (300 μL, 30% in 1:1 water/THF) and NH2OH (12 μL of 50% in water) and the reaction was stirred for 10 min. A solution of methyl 4-(4-(bromoethynyl)phenyl)-2-methyl-2-(methylsulfonyl)butanoate (9.6) in n-butylamine (750 μL, 30% in 1:1 water/THF) and NH2OH (12 μL of 50% in water, 0.201 mmol) at −10° C. was then added dropwise over 10 min and the reaction was stirred at −10° C. for 10 min. The reaction mixture was diluted with EtOAc (10 mL) and washed with 1 M citric acid (5 mL). The organic layer was washed with water (2×5 mL), sodium bicarbonate (5 mL), brine (5 mL), dried over Na2SO4 and concentrated under reduced pressure to give a thick oil (9.7), which was carried through to the next step without further purification. MS: m/z calcd for C21H24O5S 388.13, found [M+H]+ 389.2.
  • Figure US20170369426A1-20171228-C00305
  • To a stirring solution of methyl 4-(4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)phenyl)-2-methyl-2-(methylsulfonyl) butanoate (9.7) in isopropanol (1.3 mL) at 00° C. was added hydroxylamine (946 μL, 15.44 mmol, 50% in water) and the reaction was stirred at room temperature overnight. The reaction mixture was neutralized with AcOH (884 μL, 15.44 mmol) and concentrated under reduced pressure to give a crude, which was purified by RP-HPLC (0-30% ACN in water) to yield N-hydroxy-4-(4-(((trans)-2-(hydroxymethyl)cyclopropyl) buta-1,3-diynyl)phenyl)-2-methyl-2-(methylsulfonyl)butanamide (9, 22.6 mg, 22.6% yield). MS: m/z calcd for C20H23NO5S 389.13, found [M+H]+ 390.2.
  • B. Antimicrobial Activity
    • 1. Bacterial Screens and Cultures
  • Bacterial isolates were cultivated from −70° C. frozen stocks by overnight passages at 35° C. in ambient air on Mueller-Hinton agar (Beckton Dickinson, Franklin Lakes, N.J.). Clinical isolates tested were obtained from various geographically diverse hospitals in the US and abroad (Focus Diagnostics, Herndon, Va. and JMI, North Liberty, Iowa). Quality control strains were from the American Type Culture Collection (ATCC; Rockville, Md.).
    • 2. Susceptibility Testing
  • Minimum Inhibitory Concentrations (MICs) were determined by the broth microdilution method in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines. In brief, organism suspensions were adjusted to a 0.5 McFarland standard to yield a final inoculum between 3×105 and 7×105 colony-forming units (CFU)/mL. Drug dilutions and inocula were made in sterile, cation adjusted Mueller-Hinton Broth (Beckton Dickinson). An inoculum volume of 100 μL was added to wells containing 100 μL of broth with 2-fold serial dilutions of drug. All inoculated microdilution trays were incubated in ambient air at 35° C. for 18-24 hr. Following incubation, the lowest concentration of the drug that prevented visible growth (OD600 nm<0.05) was recorded as the MIC. Performance of the assay was monitored by the use of laboratory quality-control strains and levofloxacin, a compound with a defined MIC spectrum, in accordance with CLSI guidelines. Typically, compounds of the present invention have MIC values of 0.03-32 μg/mL. To this end, data for certain representative compounds is shown in Table II below.
  • TABLE II
    Minimum Inhibitory Concentrations (MICs)
    cmpd. AECO AKPN APAE
    1 A A C
    2 A C C
    3 A A A
    4 A C A
    5 A A A
    6 B C A
    7 B C B
    8 A A A
    9 A B A
    • MIC Key:
  • A=MIC's of 1.0 μg/mL or less
  • B=MIC's of greater than 1.0 μg/mL to 8.0 μg/mL
  • C=MIC's of greater than 8.0 μg/mL to 16.0 μg/mL
  • D=MIC's of greater than 16.0 μg/mL
  • * AECO is Escherichia coli ATCC25922. AKPN is Klebsiella pneumonia ATCC43816. APAE is Pseudomonas aeruginosa ATCC27853.
  • It should be understood that the organic compounds according to the invention may exhibit the phenomenon of tautomerism. As the chemical structures within this specification can only represent one of the possible tautomeric forms, it should be understood that the invention encompasses any tautomeric form of the drawn structure.
  • Furthermore, while particular embodiments of the present invention have been shown and described herein for purposes of illustration, it will be understood, of course, that the invention is not limited thereto since modifications may be made by persons skilled in the art, particularly in light of the foregoing teachings, without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
  • All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification are incorporated herein by reference, in their entirety to the extent not inconsistent with the present description.

Claims (34)

1. A compound of formula I:
Figure US20170369426A1-20171228-C00306
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein:
A is selected from the group consisting of:
(a) substituted C1-C6 alkyl, wherein at least one substituent is hydroxy; and
(b) substituted C3-C6 cycloalkyl, wherein at least one substituent is selected from hydroxy and hydroxyalkyl;
G is selected from the group consisting of:
(a) —CH═CH—C≡C—;
(b) —C≡C—CH═CH—;
(c) —C≡C—C≡C—;
Figure US20170369426A1-20171228-C00307
D is:
Figure US20170369426A1-20171228-C00308
wherein W is N or N+—O−; and
E is —C(CH3)2SCH3, —C(CH3)2S(O)CH3, —C(CH3)2S(O)2CH3, or —C(O)NHCH3.
2. A compound according to claim 1, wherein A is substituted C1-C6 alkyl, wherein at least one substituent is hydroxy.
3. A compound according to claim 2, wherein A is substituted C1-C6 alkyl, wherein at least two substituents are hydroxy.
4. A compound according to claim 2, wherein A is hydroxymethyl, hydroxyethyl, hydroxypropyl or dihydroxypropyl.
5. A compound according to claim 1, wherein A is substituted C3-C6 cycloalkyl, wherein at least one substituent is selected from hydroxy and hydroxyalkyl.
6. A compound according to claim 5, wherein A is substituted C3-C6 cycloalkyl, wherein at least one substituent is hydroxymethyl.
7. A compound according to claim 6, wherein A is hydroxymethylcyclopropyl.
8. A compound according to claim 5, wherein A is substituted C3-C6 cycloalkyl, wherein at least one substituent is hydroxy.
9. A compound according to claim 1, wherein G is —C≡C—C≡C—.
10-15. (canceled)
16. A compound according to claim 1, wherein E is —C(CH3)2SCH3.
17. A compound according to claim 1, wherein E is —C(CH3)2S(O)2CH3.
18. A compound according to claim 1, wherein E is —C(CH3)2S(O)CH3.
19. A compound according to claim 1, wherein E is —C(O)NHCH3.
20. A compound, or a pharmaceutically acceptable salt thereof, of claim 1, selected from the group consisting of:
N-hydroxy-2-(4-(((trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)phenyl)-1,6-naphthyridine-4-carboxamide (Compound 1);
N-hydroxy-2-(4-(6-hydroxyhexa-1,3-diynyl)phenyl)-1,6-naphthyridine-4-carboxamide (Compound 10);
N-hydroxy-2-(4-(5-hydroxypenta-1,3-diynyl)phenyl)-1,6-naphthyridine-4-carboxamide (Compound 11);
N-hydroxy-2-(4-(5-hydroxyhexa-1,3-diynyl)phenyl)-1,6-naphthyridine-4-carboxamide (Compound 12);
N-hydroxy-2-(4-(6-hydroxy-5-methylhexa-1,3-diynyl)phenyl)-1,6-naphthyridine-4-carboxamide (Compound 13);
2-(4-(5,6-dihydroxyhexa-1,3-diynyl)phenyl)-N-hydroxy-1,6-naphthyridine-4-carboxamide (Compound 14);
2-(4-(6,7-dihydroxyhepta-1,3-diynyl)phenyl)-N-hydroxy-1,6-naphthyridine-4-carboxamide (Compound 15);
N-hydroxy-2-(4-((3-(hydroxymethyl)cyclobutyl)buta-1,3-diynyl)phenyl)-1,6-naphthyridine-4-carboxamide (Compound 16);
N-hydroxy-2-(4-((3-hydroxycyclobutyl)buta-1,3-diynyl)phenyl)-1,6-naphthyridine-4-carboxamide (Compound 18);
N-hydroxy-2-(4-((3-(hydroxymethyl)cyclopentyl)buta-1,3-diynyl)phenyl)-1,6-naphthyridine-4-carboxamide (Compound 19);
N-hydroxy-2-(4-(((1R,2S)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)phenyl)-1,6-naphthyridine-4-carboxamide (Compound 20);
N-hydroxy-2-(4-(6-hydroxy-5-methoxyhexa-1,3-diynyl)phenyl)-1,6-naphthyridine-4-carboxamide (Compound 21);
N-hydroxy-2-(4-(7-hydroxy-6-methoxyhepta-1,3-diynyl)phenyl)-1,6-naphthyridine-4-carboxamide (Compound 22);
4-(hydroxycarbamoyl)-2-(4-(6-hydroxyhexa-1,3-diynyl)phenyl)-1,6-naphthyridine 6-oxide (Compound 23);
4-(hydroxycarbamoyl)-2-(4-(5-hydroxypenta-1,3-diynyl)phenyl)-1,6-naphthyridine 6-oxide (Compound 24);
4-(hydroxycarbamoyl)-2-(4-(5-hydroxyhexa-1,3-diynyl)phenyl)-1,6-naphthyridine 6-oxide (Compound 25);
2-(4-(6-hydroxy-5-methylhexa-1,3-diynyl)phenyl)-4-(hydroxycarbamoyl)-1,6-naphthyridine 6-oxide (Compound 26);
2-(4-(5,6-dihydroxyhexa-1,3-diynyl)phenyl)-4-(hydroxycarbamoyl)-1,6-naphthyridine 6-oxide (Compound 27);
2-(4-(6,7-dihydroxyhepta-1,3-diynyl)phenyl)-4-(hydroxycarbamoyl)-1,6-naphthyridine 6-oxide (Compound 28);
4-(hydroxycarbamoyl)-2-(4-((3-(hydroxymethyl)cyclobutyl)buta-1,3-diynyl)phenyl)-1,6-naphthyridine 6-oxide (Compound 29);
4-(hydroxycarbamoyl)-2-(4-((3-hydroxycyclobutyl)buta-1,3-diynyl)phenyl)-1,6-naphthyridine 6-oxide (Compound 30);
4-(hydroxycarbamoyl)-2-(4-((3-(hydroxymethyl)cyclopentyl)buta-1,3-diynyl)phenyl)-1,6-naphthyridine 6-oxide (Compound 31);
4-(hydroxycarbamoyl)-2-(4-(((1R,2S)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)phenyl)-1,6-naphthyridine 6-oxide (Compound 32);
2-(4-(6-hydroxy-5-methoxyhexa-1,3-diynyl)phenyl)-4-(hydroxycarbamoyl)-1,6-naphthyridine 6-oxide (Compound 33); and
2-(4-(7-hydroxy-6-methoxyhepta-1,3-diynyl)phenyl)-4-(hydroxycarbamoyl)-1,6-naphthyridine 6-oxide (Compound 34).
21. (canceled)
22. A compound of formula II:
Figure US20170369426A1-20171228-C00309
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein:
A is selected from the group consisting of:
(a) substituted C1-C6 alkyl, wherein at least one substituent is hydroxy; and
(b) substituted C3-C6 cycloalkyl, wherein at least one substituent is selected from hydroxy and hydroxyalkyl;
G is selected from the group consisting of:
a) —CH═CH—C≡C—;
(b) —C≡C—CH═CH—;
Figure US20170369426A1-20171228-C00310
D is selected from the group consisting of:
Figure US20170369426A1-20171228-C00311
wherein:
Q is O or NR, wherein R is hydrogen or an unsubstituted C1-C3 alkyl;
R1 and R2 independently are selected from the group consisting of hydrogen, substituted C1-C3 alkyl, and unsubstituted C1-C3 alkyl, or R1 and R2, together with the carbon atom to which they are attached, form an unsubstituted C3-C6 cycloalkyl group or an unsubstituted 4-6 membered heterocyclic group; and
R3 is selected from the group consisting of hydrogen, substituted C1-C6-alkyl, unsubstituted C1-C6-alkyl, substituted cycloalkyl, unsubstituted cycloalkyl, substituted cycloalkylalkyl, unsubstituted cycloalkylalkyl, substituted aryl, unsubstituted aryl, substituted arylalkyl, unsubstituted arylalkyl, substituted heterocyclyl, or unsubstituted heterocyclyl, substituted heterocyclylalkyl, unsubstituted heterocyclylalkyl, substituted heteroaryl, unsubstituted heteroaryl, substituted heteroarylalkyl, and unsubstituted heteroarylalkyl.
23. The compound of claim 22, wherein A is substituted C1-C6 alkyl, wherein at least one substituent is hydroxy.
24. The compound of claim 23, wherein A is substituted C1-C6 alkyl, wherein at least two substituents are hydroxy.
25. The compound of claim 23, wherein A is hydroxymethyl, hydroxyethyl, hydroxypropyl or dihydroxypropyl.
26. The compound of claim 22, wherein A is substituted C3-C6 cycloalkyl, wherein at least one substituent is selected from hydroxy and hydroxyalkyl.
27. The compound of claim 26, wherein A is substituted C3-C6 cycloalkyl, wherein at least one substituent is hydroxymethyl.
28. The compound of claim 26, wherein A is substituted C3-C6 cycloalkyl, wherein at least one substituent is hydroxy.
29. A compound, or a pharmaceutically acceptable salt thereof, according to claim 22, wherein the compound is selected from the group consisting of:
N-hydroxy-4-(4-(4-(((1S,2S)-2-(hydroxymethyl)cyclopropyl)ethynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 51);
N-hydroxy-4-(4-(4-(((1R,2R)-2-(hydroxymethyl)cyclopropyl)ethynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 52);
N-hydroxy-4-(4-(4-(((1R,2S)-2-(hydroxymethyl)cyclopropyl)ethynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 53);
N-hydroxy-4-(4-(4-(((1S,2R)-2-(hydroxymethyl)cyclopropyl)ethynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 54);
N-hydroxy-4-(4-(4-(3-hydroxyprop-1-ynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 55);
N-hydroxy-4-(4-(4-(4-hydroxybut-1-ynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 56);
N-hydroxy-4-(4-(4-(3-hydroxybut-1-ynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 57);
N-hydroxy-4-(4-(4-(4-hydroxy-3-methylbut-1-ynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 58);
4-(4-(4-(3,4-dihydroxybut-1-ynyl)phenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide (Compound 59);
4-(4-(4-(4,5-dihydroxypent-1-ynyl)phenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide (Compound 60);
N-hydroxy-4-(4-(4-((3-hydroxycyclobutyl)ethynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 61);
N-hydroxy-4-(4-(4-((3-(hydroxymethyl)cyclobutyl)ethynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 62);
N-hydroxy-4-(4-(4-((3-(hydroxymethyl)cyclopentyl)ethynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 63);
N-hydroxy-4-(4-(4-(4-hydroxy-3-methoxybut-1-ynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 64);
N-hydroxy-4-(4-(4-(5-hydroxy-4-methoxypent-1-ynyl)phenyl)-2-oxopyridin-1(2H)-yl)-2 methyl-2-(methylsulfonyl)butanamide (Compound 65);
N-hydroxy-4-(4-(4-((E)-2-((1R,2S)-2-(hydroxymethyl)cyclopropyl)vinyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 83);
N-hydroxy-4-(4-(4-((E)-2-((1S,2R)-2-(hydroxymethyl)cyclopropyl)vinyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 84);
N-hydroxy-4-(4-(4-((E)-2-((1S,2S)-2-(hydroxymethyl)cyclopropyl)vinyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 85);
N-hydroxy-4-(4-(4-((E)-2-((1R,2R)-2-(hydroxymethyl)cyclopropyl)vinyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 86);
(E)-N-hydroxy-4-(4-(4-(3-hydroxyprop-1-enyl)phenyl)-2-oxopyridin-1(2H)-yl-2-methyl-2-(methylsulfonyl)butanamide (Compound 87);
(E)-N-hydroxy-4-(4-(4-(4-hydroxybut-1-enyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 88);
(E)-N-hydroxy-4-(4-(4-(3-hydroxybut-1-enyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 89);
(E)-N-hydroxy-4-(4-(4-(4-hydroxy-3-methylbut-1-enyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 90);
(E)-4-(4-(4-(3,4-dihydroxybut-1-enyl)phenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide (Compound 91);
(E)-4-(4-(4-(4,5-dihydroxypent-1-enyl)phenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide (Compound 92);
(E)-N-hydroxy-4-(4-(4-(2-(3-hydroxycyclobutyl)vinyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 93);
(E)-N-hydroxy-4-(4-(4-(2-(3-(hydroxymethyl)cyclobutyl)vinyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 94);
(E)-N-hydroxy-4-(4-(4-(2-(3-(hydroxymethyl)cyclopentyl)vinyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 95);
(E)-N-hydroxy-4-(4-(4-(4-hydroxy-3-methoxybut-1-enyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 96); and
(E)-N-hydroxy-4-(4-(4-(5-hydroxy-4-methoxypent-1-enyl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide (Compound 97).
30. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound, or a stereoisomer or pharmaceutically acceptable salt thereof, according to claim 1
31. A method for treating a bacterial infection in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound, or a stereoisomer or pharmaceutically acceptable salt thereof, according to claim 1.
32. A method according to claim 31, wherein said bacterial infection is a gram-negative bacterial infection.
33. A method according to claim 32, wherein said gram-negative bacterial infection is Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia cepacia, Alcaligenes xylosoxidans, Enterobacteriaceae, Haemophilus, Francisellaceae, or a Neisseria species.
34. A method for treating a bacterial infection in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 30.
35. A method according to claim 34, wherein said bacterial infection is a gram-negative bacterial infection.
36. A method according to claim 35, wherein said gram-negative bacterial infection is Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia cepacia, Alcaligenes xylosoxidans, Enterobacteriaceae, Haemophilus, Francisellaceae, or a Neisseria species.
37. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound, or a stereoisomer or pharmaceutically acceptable salt thereof, according to claim 22.
38. A method for treating a bacterial infection in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound, or a stereoisomer or pharmaceutically acceptable salt thereof, according to claim 22.
39. A method for treating a bacterial infection in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition, according to claim 37.
US15/615,276 2012-05-10 2017-06-06 Antibacterial agents Abandoned US20170369426A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/615,276 US20170369426A1 (en) 2012-05-10 2017-06-06 Antibacterial agents

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261645439P 2012-05-10 2012-05-10
PCT/US2013/040571 WO2013170165A1 (en) 2012-05-10 2013-05-10 Antibacterial agents
US14/537,048 US9403758B2 (en) 2012-05-10 2014-11-10 Antibacterial agents
US15/179,751 US9701622B2 (en) 2012-05-10 2016-06-10 Antibacterial agents
US15/615,276 US20170369426A1 (en) 2012-05-10 2017-06-06 Antibacterial agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/179,751 Continuation US9701622B2 (en) 2012-05-10 2016-06-10 Antibacterial agents

Publications (1)

Publication Number Publication Date
US20170369426A1 true US20170369426A1 (en) 2017-12-28

Family

ID=48485512

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/537,048 Expired - Fee Related US9403758B2 (en) 2012-05-10 2014-11-10 Antibacterial agents
US15/179,751 Expired - Fee Related US9701622B2 (en) 2012-05-10 2016-06-10 Antibacterial agents
US15/615,276 Abandoned US20170369426A1 (en) 2012-05-10 2017-06-06 Antibacterial agents

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US14/537,048 Expired - Fee Related US9403758B2 (en) 2012-05-10 2014-11-10 Antibacterial agents
US15/179,751 Expired - Fee Related US9701622B2 (en) 2012-05-10 2016-06-10 Antibacterial agents

Country Status (3)

Country Link
US (3) US9403758B2 (en)
EP (1) EP2847168A1 (en)
WO (1) WO2013170165A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107021895A (en) 2007-06-12 2017-08-08 尔察祯有限公司 Antiseptic
EP2847168A1 (en) 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents
EP2948450A4 (en) * 2013-01-28 2016-11-09 Viamet Pharmaceuticals Inc Metalloenzyme inhibitor compounds
HUE043922T2 (en) * 2013-03-15 2019-09-30 Fujifilm Toyama Chemical Co Ltd Novel hydroxamic acid derivative or salt thereof
AU2014306451B2 (en) * 2013-08-16 2019-01-17 Duke University Substituted hydroxamic acid compounds
JP2016210682A (en) * 2013-10-18 2016-12-15 大正製薬株式会社 Hydroxamic acid derivative
JP2016210683A (en) * 2013-10-18 2016-12-15 大正製薬株式会社 Hydroxamic acid derivative
JPWO2015056799A1 (en) * 2013-10-18 2017-03-09 大正製薬株式会社 Hydroxamic acid derivatives
AU2014368619B2 (en) 2013-12-19 2018-11-22 Idorsia Pharmaceuticals Ltd Antibacterial 1H-indazole and 1H-indole derivatives
AR099612A1 (en) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd ANTIBACTERIAL DERIVATIVES OF 1,2-DIHIDRO-3H-PIRROLO [1,2-C] IMIDAZOL-3-ONA
CA2948077A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
SG11201701955UA (en) * 2014-09-12 2017-04-27 Toyama Chemical Co Ltd Method for using novel hydroxamic acid derivative and antibacterial substance in combination
CA2960949A1 (en) 2014-09-12 2016-03-17 Tatsuya Honda Novel pharmaceutical composition containing hydroxamic acid derivative or salt thereof
CA2964113A1 (en) 2014-10-14 2016-04-21 La Jolla Institute Of Allergy & Immunology Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
EP3221300B1 (en) * 2014-11-19 2019-03-20 Idorsia Pharmaceuticals Ltd Antibacterial benzothiazole derivatives
AR105646A1 (en) * 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd ANTIBACTERIAL AGENTS OF 1,2-DIHIDRO-3H-PIRROLO [1,2-C] IMIDAZOL-3-ONA SUBSTITUTED
AR105889A1 (en) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd ANTIBACTERIAL COMPOUNDS 1,2-DIHIDRO-3H-PIRROLO [1,2-C] IMIDAZOL-3-ONA SUBSTITUTED
WO2017170885A1 (en) * 2016-03-31 2017-10-05 富山化学工業株式会社 Crystals of novel hydroxamic acid derivative, method for producing same, and pharmaceutical composition
AR108864A1 (en) 2016-06-23 2018-10-03 Achaogen Inc ANTIBACTERIAL AGENTS
US10285437B2 (en) * 2016-08-25 2019-05-14 Tamatha Lagina Russell Attachment device for hand-held vaporizer
ES2891025T3 (en) * 2016-09-28 2022-01-25 Dong A St Co Ltd Tetrahydropyridine derivatives and their use as antibacterial agents
EP3619210A4 (en) * 2017-05-01 2020-12-02 Sanford Burnham Prebys Medical Discovery Institute LOW MOLECULAR PROTEIN TYROSINE PHOSPHATASE (LMPTP) INHIBITORS AND USES THEREOF
GB2562777A (en) * 2017-05-25 2018-11-28 Taisho Pharmaceutical Co Ltd Novel alpha-amino amide derivatives
CA3090833A1 (en) * 2018-02-10 2019-08-15 Kbp Biosciences Co., Ltd. Compound acting as antibiotics
CN111867600A (en) * 2018-03-15 2020-10-30 辉瑞大药厂 Pyridone and pyrimidinone phosphates and borates used as antibacterial agents

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2772281A (en) 1954-12-23 1956-11-27 Merck & Co Inc Synthesis of 4-amino-3-isoxazolidone and its derivatives
GB9503749D0 (en) 1995-02-24 1995-04-12 British Biotech Pharm Synthesis of hydroxamic acid derivatives
EP0850215B1 (en) 1995-07-26 2000-10-18 Pfizer Inc. N-(aroyl)glycine hydroxamic acid derivatives and related compounds
US5925659A (en) 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
WO1998015525A1 (en) 1996-10-07 1998-04-16 Sumitomo Pharmaceuticals Co., Ltd. Hydroxamic acids
WO1998018754A1 (en) 1996-10-28 1998-05-07 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
AR016751A1 (en) 1996-11-22 2001-08-01 Athena Neurosciences Inc METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHOD
GB9715030D0 (en) 1997-07-18 1997-09-24 British Biotech Pharm Metalloproteinase inhibitors
IL134273A0 (en) 1997-07-31 2001-04-30 Procter & Gamble Acyclic metalloprotease inhibitors
EP1024134A4 (en) 1997-10-09 2003-05-14 Ono Pharmaceutical Co Aminobutanoic acid derivatives
KR100600518B1 (en) 1998-02-07 2006-07-13 브리티쉬 바이오테크 파마슈티칼스 리미티드 Antimicrobial
WO2000002904A1 (en) 1998-07-08 2000-01-20 Harald Tschesche Matrix metalloproteinase inhibitors containing aminomalonic acid derivatives and peptide backbone modified derivatives thereof
GB9901863D0 (en) 1999-01-29 1999-03-17 British Biotech Pharm Antibacterial agents
AU4180900A (en) 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
JP2002541197A (en) 1999-04-09 2002-12-03 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド Antibacterial agent
DE60115279T2 (en) 2000-09-29 2006-12-28 Topotarget Uk Ltd., Abingdon CARBOXIC ACID DERIVATIVES CONTAIN AN AMID GROUP AS HDAC INHIBITORS
WO2002030873A1 (en) 2000-10-10 2002-04-18 Fujisawa Pharmaceutical Co., Ltd. Mmp inhibitor
US7323596B2 (en) 2000-12-21 2008-01-29 De Novo Pharmaceuticals Ltd. Antimicrobial agents
US7064215B2 (en) 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
SI1511472T1 (en) 2002-05-29 2009-08-31 Merck & Co Inc Compounds useful in the treatment of anthrax and inhibiting lethal factor
EP1539744A4 (en) 2002-07-11 2007-06-06 Vicuron Pharm Inc N-hydroxyamide derivatives possessing antibacterial activity
US7282608B2 (en) 2002-10-17 2007-10-16 Methylgene, Inc. Inhibitors of histone deacetylase
EP1618087B1 (en) 2003-01-08 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Antibacterial agents
GT200600196A (en) 2005-05-23 2007-01-15 N-FORMIL HYDROXYLAMINE COMPOUNDS
US7705037B2 (en) 2005-06-07 2010-04-27 Novartis Ag 1-substituted pyrrolidin-2-ones and use thereof as peptide deformylase inhibitors
US20070066646A1 (en) 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
WO2007064732A1 (en) 2005-12-01 2007-06-07 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
CA2634005C (en) 2005-12-15 2012-01-03 Vicuron Pharmaceuticals Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2008027466A1 (en) 2006-08-31 2008-03-06 Schering Corporation Hydantoin derivatives useful as antibacterial agents
CN101209974A (en) 2006-12-31 2008-07-02 天津药物研究院 Hydroxamic acids derivatives and use thereof
JP5227304B2 (en) * 2007-02-28 2013-07-03 大正製薬株式会社 Novel hydroxamic acid derivatives
CN107021895A (en) 2007-06-12 2017-08-08 尔察祯有限公司 Antiseptic
JP2011525927A (en) 2008-06-25 2011-09-29 シェーリング コーポレイション Synthesis and use of heterocyclic antibacterial agents
WO2010017060A1 (en) 2008-08-04 2010-02-11 Schering Corporation Urea derivatives as antibacterial agents
JP5455913B2 (en) 2008-08-27 2014-03-26 大正製薬株式会社 Novel hydroxamic acid derivatives having naphthyridine-N-oxide
US8372885B2 (en) 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
CA2735929C (en) 2008-09-19 2013-12-17 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
WO2011005355A1 (en) 2009-05-07 2011-01-13 Achaogen, Inc. Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
CA2774250C (en) 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
US8664401B2 (en) * 2009-12-16 2014-03-04 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
PH12012502087A1 (en) 2010-04-20 2015-04-15 Taisho Pharmaceutical Co Ltd Novel hydroxamic acid derivative
AR083760A1 (en) 2010-11-10 2013-03-20 Achaogen Inc ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS
WO2013039947A1 (en) 2011-09-12 2013-03-21 Achaogen, Inc. Polymorphs of n-((s)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(((1r,2r)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamide
EP2847162A1 (en) 2012-05-09 2015-03-18 Achaogen, Inc. Antibacterial agents
EP2847168A1 (en) 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents

Also Published As

Publication number Publication date
EP2847168A1 (en) 2015-03-18
WO2013170165A1 (en) 2013-11-14
US9403758B2 (en) 2016-08-02
US20160016895A1 (en) 2016-01-21
US9701622B2 (en) 2017-07-11
US20160280639A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
US9701622B2 (en) Antibacterial agents
US20150175530A1 (en) Antibacterial agents
TWI574941B (en) Antibacterial agents
SG190243A1 (en) Hydroxamic acid derivatives and their use in the treatment of bacterial infections
WO2014165075A1 (en) Antibacterial agents
US8153843B2 (en) Antibacterial agents
US8604069B2 (en) Amide compound and medicinal use thereof
JP2002537286A (en) Thioamide derivative
JP2006519772A5 (en)
US7879911B2 (en) Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
JP2017505304A (en) 12-EPI-Pleuromutilin
US20150203444A1 (en) Polymorphs of n-((s)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(((1r,2r)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamide
US6878732B2 (en) NK1 antagonists
US20240156788A1 (en) Substituted 2-aminobenzimidazoles analogs as antibiofilm agents
CN102014635B (en) As cystatin containing difluoro compound

Legal Events

Date Code Title Description
AS Assignment

Owner name: ACHAOGEN, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PATTERSON, BRIAN D.;LU, QING;AGGEN, JAMES BRADLEY;AND OTHERS;SIGNING DATES FROM 20150114 TO 20150122;REEL/FRAME:042620/0011

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE